<html lang="en-US"><head>
	<!-- OneTrust Cookies Consent Notice start for beigene.com -->
<script type="text/javascript" async="" src="https://snap.licdn.com/li.lms-analytics/insight.min.js"></script><script async="" src="//static.ads-twitter.com/uwt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-KVJG7B2"></script><script type="text/javascript" src="https://cdn.cookielaw.org/consent/9bc4e7b2-9ff6-4ce8-8210-c3575df3d9c7/OtAutoBlock.js"></script>
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="9bc4e7b2-9ff6-4ce8-8210-c3575df3d9c7"></script>
<script type="text/javascript">
function OptanonWrapper() { }
</script>
<!-- OneTrust Cookies Consent Notice end for beigene.com -->
        <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KVJG7B2');</script>
    <!-- End Google Tag Manager -->

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <!-- OPEN GRAPH -->
        <meta property="og:title" content="Pipeline">
    <meta property="og:type" content="Website">
    <meta property="og:url" content="https://www.beigene.com/our-science-and-medicines/pipeline">
    <meta property="og:site_name" content="BeiGene">

    <!-- TWITTER -->
        <meta name="twitter:title" content="Pipeline">
    <meta name="twitter:type" content="Website">
    <meta name="twitter:url" content="https://www.beigene.com/our-science-and-medicines/pipeline">
    <meta name="twitter:site_name" content="BeiGene">

	<!-- Twitter universal website tag code -->
<script>
!function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments);
},s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js',
a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script');
// Insert Twitter Pixel ID and Standard Event data below
twq('init','o83cw');
twq('track','PageView');
</script>
<!-- End Twitter universal website tag code -->
    <meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">

	<!-- This site is optimized with the Yoast SEO plugin v19.3 - https://yoast.com/wordpress/plugins/seo/ -->
	<title>Our Pipeline | BeiGene</title>
	<meta name="description" content="We are pursuing a broad and deep pipeline that addresses 80% of world’s cancers by incidence.">
	<link rel="canonical" href="https://www.beigene.com/our-science-and-medicines/pipeline/">
	<meta property="og:locale" content="en_US">
	<meta property="og:type" content="article">
	<meta property="og:title" content="Our Pipeline | BeiGene">
	<meta property="og:description" content="We are pursuing a broad and deep pipeline that addresses 80% of world’s cancers by incidence.">
	<meta property="og:url" content="https://www.beigene.com/our-science-and-medicines/pipeline/">
	<meta property="og:site_name" content="BeiGene">
	<meta property="article:modified_time" content="2022-05-04T15:38:35+00:00">
	<meta property="og:image" content="https://www.beigene.com/wp-content/uploads/2022/04/logo_beigene_social.png">
	<meta property="og:image:width" content="600">
	<meta property="og:image:height" content="315">
	<meta property="og:image:type" content="image/png">
	<meta name="twitter:card" content="summary_large_image">
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://www.beigene.com/#organization","name":"Beigene","url":"https://www.beigene.com/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.beigene.com/#/schema/logo/image/","url":"https://www.beigene.com/wp-content/uploads/2022/04/logo_beigene_social.png","contentUrl":"https://www.beigene.com/wp-content/uploads/2022/04/logo_beigene_social.png","width":600,"height":315,"caption":"Beigene"},"image":{"@id":"https://www.beigene.com/#/schema/logo/image/"}},{"@type":"WebSite","@id":"https://www.beigene.com/#website","url":"https://www.beigene.com/","name":"BeiGene","description":"Cancer Has No Borders. Neither Do We.","publisher":{"@id":"https://www.beigene.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.beigene.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https://www.beigene.com/our-science-and-medicines/pipeline/","url":"https://www.beigene.com/our-science-and-medicines/pipeline/","name":"Our Pipeline | BeiGene","isPartOf":{"@id":"https://www.beigene.com/#website"},"datePublished":"2022-03-11T22:28:14+00:00","dateModified":"2022-05-04T15:38:35+00:00","description":"We are pursuing a broad and deep pipeline that addresses 80% of world’s cancers by incidence.","breadcrumb":{"@id":"https://www.beigene.com/our-science-and-medicines/pipeline/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.beigene.com/our-science-and-medicines/pipeline/"]}]},{"@type":"BreadcrumbList","@id":"https://www.beigene.com/our-science-and-medicines/pipeline/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.beigene.com/"},{"@type":"ListItem","position":2,"name":"Our Science &#038; Medicines","item":"https://www.beigene.com/our-science-and-medicines/"},{"@type":"ListItem","position":3,"name":"Pipeline"}]}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel="dns-prefetch" href="//s.w.org">
<script>
window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/www.beigene.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.0.1"}};
/*! This file is auto-generated */
!function(e,a,t){var n,r,o,i=a.createElement("canvas"),p=i.getContext&&i.getContext("2d");function s(e,t){var a=String.fromCharCode,e=(p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,e),0,0),i.toDataURL());return p.clearRect(0,0,i.width,i.height),p.fillText(a.apply(this,t),0,0),e===i.toDataURL()}function c(e){var t=a.createElement("script");t.src=e,t.defer=t.type="text/javascript",a.getElementsByTagName("head")[0].appendChild(t)}for(o=Array("flag","emoji"),t.supports={everything:!0,everythingExceptFlag:!0},r=0;r<o.length;r++)t.supports[o[r]]=function(e){if(!p||!p.fillText)return!1;switch(p.textBaseline="top",p.font="600 32px Arial",e){case"flag":return s([127987,65039,8205,9895,65039],[127987,65039,8203,9895,65039])?!1:!s([55356,56826,55356,56819],[55356,56826,8203,55356,56819])&&!s([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]);case"emoji":return!s([129777,127995,8205,129778,127999],[129777,127995,8203,129778,127999])}return!1}(o[r]),t.supports.everything=t.supports.everything&&t.supports[o[r]],"flag"!==o[r]&&(t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&t.supports[o[r]]);t.supports.everythingExceptFlag=t.supports.everythingExceptFlag&&!t.supports.flag,t.DOMReady=!1,t.readyCallback=function(){t.DOMReady=!0},t.supports.everything||(n=function(){t.readyCallback()},a.addEventListener?(a.addEventListener("DOMContentLoaded",n,!1),e.addEventListener("load",n,!1)):(e.attachEvent("onload",n),a.attachEvent("onreadystatechange",function(){"complete"===a.readyState&&t.readyCallback()})),(e=t.source||{}).concatemoji?c(e.concatemoji):e.wpemoji&&e.twemoji&&(c(e.twemoji),c(e.wpemoji)))}(window,document,window._wpemojiSettings);
</script><script src="https://www.beigene.com/wp-includes/js/wp-emoji-release.min.js?ver=6.0.1" type="text/javascript" defer=""></script>
<style type="text/css">
img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 0.07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}
</style>
	<link rel="stylesheet" id="global-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/global.css?ver=1" type="text/css" media="all">
<link rel="stylesheet" id="header-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/header.css?ver=1" type="text/css" media="all">
<link rel="stylesheet" id="wp-block-library-css" href="https://www.beigene.com/wp-includes/css/dist/block-library/style.min.css?ver=6.0.1" type="text/css" media="all">
<style id="global-styles-inline-css" type="text/css">
body{--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--color--dark-blue: #003a70;--wp--preset--color--bright-red: #ed1c24;--wp--preset--color--sunflower: #ffc72c;--wp--preset--color--burgundy: #a11d22;--wp--preset--color--autumn-leaf-alt: #c65300;--wp--preset--color--autumn-leaf: #e97600;--wp--preset--color--cerulean: #00677f;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel="stylesheet" id="bootstrap-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/libs/css/bootstrap.css?ver=5.1.3" type="text/css" media="all">
<link rel="stylesheet" id="boilerplate-typography-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/boilerplate/typography.css?ver=1" type="text/css" media="all">
<link rel="https://api.w.org/" href="https://www.beigene.com/wp-json/"><link rel="alternate" type="application/json" href="https://www.beigene.com/wp-json/wp/v2/pages/152"><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://www.beigene.com/xmlrpc.php?rsd">
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://www.beigene.com/wp-includes/wlwmanifest.xml"> 
<meta name="generator" content="WordPress 6.0.1">
<link rel="shortlink" href="https://www.beigene.com/?p=152">
<link rel="alternate" type="application/json+oembed" href="https://www.beigene.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.beigene.com%2Four-science-and-medicines%2Fpipeline%2F">
<link rel="alternate" type="text/xml+oembed" href="https://www.beigene.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.beigene.com%2Four-science-and-medicines%2Fpipeline%2F&amp;format=xml">
<link rel="icon" href="https://www.beigene.com/wp-content/uploads/2022/04/logo.svg" sizes="32x32">
<link rel="icon" href="https://www.beigene.com/wp-content/uploads/2022/04/logo.svg" sizes="192x192">
<link rel="apple-touch-icon" href="https://www.beigene.com/wp-content/uploads/2022/04/logo.svg">
<meta name="msapplication-TileImage" content="https://www.beigene.com/wp-content/uploads/2022/04/logo.svg">
<script src="https://cdn.cookielaw.org/scripttemplates/6.36.0/otBannerSdk.js" async="" type="text/javascript"></script><style id="onetrust-style">#onetrust-banner-sdk{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}#onetrust-banner-sdk .onetrust-vendors-list-handler{cursor:pointer;color:#1f96db;font-size:inherit;font-weight:bold;text-decoration:none;margin-left:5px}#onetrust-banner-sdk .onetrust-vendors-list-handler:hover{color:#1f96db}#onetrust-banner-sdk:focus{outline:2px solid #000;outline-offset:-2px}#onetrust-banner-sdk a:focus{outline:2px solid #000}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{outline-offset:1px}#onetrust-banner-sdk .ot-close-icon,#onetrust-pc-sdk .ot-close-icon,#ot-sync-ntfy .ot-close-icon{background-image:url("data:image/svg+xml;base64,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");background-size:contain;background-repeat:no-repeat;background-position:center;height:12px;width:12px}#onetrust-banner-sdk .powered-by-logo,#onetrust-banner-sdk .ot-pc-footer-logo a,#onetrust-pc-sdk .powered-by-logo,#onetrust-pc-sdk .ot-pc-footer-logo a,#ot-sync-ntfy .powered-by-logo,#ot-sync-ntfy .ot-pc-footer-logo a{background-size:contain;background-repeat:no-repeat;background-position:center;height:25px;width:152px;display:block;text-decoration:none;font-size:0.75em}#onetrust-banner-sdk .powered-by-logo:hover,#onetrust-banner-sdk .ot-pc-footer-logo a:hover,#onetrust-pc-sdk .powered-by-logo:hover,#onetrust-pc-sdk .ot-pc-footer-logo a:hover,#ot-sync-ntfy .powered-by-logo:hover,#ot-sync-ntfy .ot-pc-footer-logo a:hover{color:#565656}#onetrust-banner-sdk h3 *,#onetrust-banner-sdk h4 *,#onetrust-banner-sdk h6 *,#onetrust-banner-sdk button *,#onetrust-banner-sdk a[data-parent-id] *,#onetrust-pc-sdk h3 *,#onetrust-pc-sdk h4 *,#onetrust-pc-sdk h6 *,#onetrust-pc-sdk button *,#onetrust-pc-sdk a[data-parent-id] *,#ot-sync-ntfy h3 *,#ot-sync-ntfy h4 *,#ot-sync-ntfy h6 *,#ot-sync-ntfy button *,#ot-sync-ntfy a[data-parent-id] *{font-size:inherit;font-weight:inherit;color:inherit}#onetrust-banner-sdk .ot-hide,#onetrust-pc-sdk .ot-hide,#ot-sync-ntfy .ot-hide{display:none !important}#onetrust-banner-sdk button.ot-link-btn:hover,#onetrust-pc-sdk button.ot-link-btn:hover,#ot-sync-ntfy button.ot-link-btn:hover{text-decoration:underline;opacity:1}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-column{padding:0}#onetrust-pc-sdk .ot-sdk-container{padding-right:0}#onetrust-pc-sdk .ot-sdk-row{flex-direction:initial;width:100%}#onetrust-pc-sdk [type="checkbox"]:checked,#onetrust-pc-sdk [type="checkbox"]:not(:checked){pointer-events:initial}#onetrust-pc-sdk [type="checkbox"]:disabled+label::before,#onetrust-pc-sdk [type="checkbox"]:disabled+label:after,#onetrust-pc-sdk [type="checkbox"]:disabled+label{pointer-events:none;opacity:0.7}#onetrust-pc-sdk #vendor-list-content{transform:translate3d(0, 0, 0)}#onetrust-pc-sdk li input[type="checkbox"]{z-index:1}#onetrust-pc-sdk li .ot-checkbox label{z-index:2}#onetrust-pc-sdk li .ot-checkbox input[type="checkbox"]{height:auto;width:auto}#onetrust-pc-sdk li .host-title a,#onetrust-pc-sdk li .ot-host-name a,#onetrust-pc-sdk li .accordion-text,#onetrust-pc-sdk li .ot-acc-txt{z-index:2;position:relative}#onetrust-pc-sdk input{margin:3px 0.1ex}#onetrust-pc-sdk .pc-logo,#onetrust-pc-sdk .ot-pc-logo{height:60px;width:180px;background-position:center;background-size:contain;background-repeat:no-repeat}#onetrust-pc-sdk .screen-reader-only,#onetrust-pc-sdk .ot-scrn-rdr,.ot-sdk-cookie-policy .screen-reader-only,.ot-sdk-cookie-policy .ot-scrn-rdr{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}#onetrust-pc-sdk.ot-fade-in,.onetrust-pc-dark-filter.ot-fade-in,#onetrust-banner-sdk.ot-fade-in{animation-name:onetrust-fade-in;animation-duration:400ms;animation-timing-function:ease-in-out}#onetrust-pc-sdk.ot-hide{display:none !important}.onetrust-pc-dark-filter.ot-hide{display:none !important}#ot-sdk-btn.ot-sdk-show-settings,#ot-sdk-btn.optanon-show-settings{color:#68b631;border:1px solid #68b631;height:auto;white-space:normal;word-wrap:break-word;padding:0.8em 2em;font-size:0.8em;line-height:1.2;cursor:pointer;-moz-transition:0.1s ease;-o-transition:0.1s ease;-webkit-transition:1s ease;transition:0.1s ease}#ot-sdk-btn.ot-sdk-show-settings:hover,#ot-sdk-btn.optanon-show-settings:hover{color:#fff;background-color:#68b631}.onetrust-pc-dark-filter{background:rgba(0,0,0,0.5);z-index:2147483646;width:100%;height:100%;overflow:hidden;position:fixed;top:0;bottom:0;left:0}@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}.ot-cookie-label{text-decoration:underline}@media only screen and (min-width: 426px) and (max-width: 896px) and (orientation: landscape){#onetrust-pc-sdk p{font-size:0.75em}}#onetrust-banner-sdk .banner-option-input:focus+label{outline:1px solid #000;outline-style:auto}.category-vendors-list-handler+a:focus,.category-vendors-list-handler+a:focus-visible{outline:2px solid #000}#onetrust-pc-sdk .ot-userid-title{margin-top:10px}#onetrust-pc-sdk .ot-userid-title>span,#onetrust-pc-sdk .ot-userid-timestamp>span{font-weight:700}#onetrust-pc-sdk .ot-userid-desc{font-style:italic}#onetrust-pc-sdk .ot-host-desc a{pointer-events:initial}#onetrust-pc-sdk .ot-ven-hdr>p a{position:relative;z-index:2;pointer-events:initial}
#onetrust-banner-sdk,#onetrust-pc-sdk,#ot-sdk-cookie-policy,#ot-sync-ntfy{font-size:16px}#onetrust-banner-sdk *,#onetrust-banner-sdk ::after,#onetrust-banner-sdk ::before,#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before,#ot-sdk-cookie-policy *,#ot-sdk-cookie-policy ::after,#ot-sdk-cookie-policy ::before,#ot-sync-ntfy *,#ot-sync-ntfy ::after,#ot-sync-ntfy ::before{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}#onetrust-banner-sdk div,#onetrust-banner-sdk span,#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-banner-sdk p,#onetrust-banner-sdk img,#onetrust-banner-sdk svg,#onetrust-banner-sdk button,#onetrust-banner-sdk section,#onetrust-banner-sdk a,#onetrust-banner-sdk label,#onetrust-banner-sdk input,#onetrust-banner-sdk ul,#onetrust-banner-sdk li,#onetrust-banner-sdk nav,#onetrust-banner-sdk table,#onetrust-banner-sdk thead,#onetrust-banner-sdk tr,#onetrust-banner-sdk td,#onetrust-banner-sdk tbody,#onetrust-banner-sdk .ot-main-content,#onetrust-banner-sdk .ot-toggle,#onetrust-banner-sdk #ot-content,#onetrust-banner-sdk #ot-pc-content,#onetrust-banner-sdk .checkbox,#onetrust-pc-sdk div,#onetrust-pc-sdk span,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#onetrust-pc-sdk p,#onetrust-pc-sdk img,#onetrust-pc-sdk svg,#onetrust-pc-sdk button,#onetrust-pc-sdk section,#onetrust-pc-sdk a,#onetrust-pc-sdk label,#onetrust-pc-sdk input,#onetrust-pc-sdk ul,#onetrust-pc-sdk li,#onetrust-pc-sdk nav,#onetrust-pc-sdk table,#onetrust-pc-sdk thead,#onetrust-pc-sdk tr,#onetrust-pc-sdk td,#onetrust-pc-sdk tbody,#onetrust-pc-sdk .ot-main-content,#onetrust-pc-sdk .ot-toggle,#onetrust-pc-sdk #ot-content,#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk .checkbox,#ot-sdk-cookie-policy div,#ot-sdk-cookie-policy span,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy p,#ot-sdk-cookie-policy img,#ot-sdk-cookie-policy svg,#ot-sdk-cookie-policy button,#ot-sdk-cookie-policy section,#ot-sdk-cookie-policy a,#ot-sdk-cookie-policy label,#ot-sdk-cookie-policy input,#ot-sdk-cookie-policy ul,#ot-sdk-cookie-policy li,#ot-sdk-cookie-policy nav,#ot-sdk-cookie-policy table,#ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy tr,#ot-sdk-cookie-policy td,#ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy .ot-main-content,#ot-sdk-cookie-policy .ot-toggle,#ot-sdk-cookie-policy #ot-content,#ot-sdk-cookie-policy #ot-pc-content,#ot-sdk-cookie-policy .checkbox,#ot-sync-ntfy div,#ot-sync-ntfy span,#ot-sync-ntfy h1,#ot-sync-ntfy h2,#ot-sync-ntfy h3,#ot-sync-ntfy h4,#ot-sync-ntfy h5,#ot-sync-ntfy h6,#ot-sync-ntfy p,#ot-sync-ntfy img,#ot-sync-ntfy svg,#ot-sync-ntfy button,#ot-sync-ntfy section,#ot-sync-ntfy a,#ot-sync-ntfy label,#ot-sync-ntfy input,#ot-sync-ntfy ul,#ot-sync-ntfy li,#ot-sync-ntfy nav,#ot-sync-ntfy table,#ot-sync-ntfy thead,#ot-sync-ntfy tr,#ot-sync-ntfy td,#ot-sync-ntfy tbody,#ot-sync-ntfy .ot-main-content,#ot-sync-ntfy .ot-toggle,#ot-sync-ntfy #ot-content,#ot-sync-ntfy #ot-pc-content,#ot-sync-ntfy .checkbox{font-family:inherit;font-weight:normal;-webkit-font-smoothing:auto;letter-spacing:normal;line-height:normal;padding:0;margin:0;height:auto;min-height:0;max-height:none;width:auto;min-width:0;max-width:none;border-radius:0;border:none;clear:none;float:none;position:static;bottom:auto;left:auto;right:auto;top:auto;text-align:left;text-decoration:none;text-indent:0;text-shadow:none;text-transform:none;white-space:normal;background:none;overflow:visible;vertical-align:baseline;visibility:visible;z-index:auto;box-shadow:none}#onetrust-banner-sdk label:before,#onetrust-banner-sdk label:after,#onetrust-banner-sdk .checkbox:after,#onetrust-banner-sdk .checkbox:before,#onetrust-pc-sdk label:before,#onetrust-pc-sdk label:after,#onetrust-pc-sdk .checkbox:after,#onetrust-pc-sdk .checkbox:before,#ot-sdk-cookie-policy label:before,#ot-sdk-cookie-policy label:after,#ot-sdk-cookie-policy .checkbox:after,#ot-sdk-cookie-policy .checkbox:before,#ot-sync-ntfy label:before,#ot-sync-ntfy label:after,#ot-sync-ntfy .checkbox:after,#ot-sync-ntfy .checkbox:before{content:"";content:none}
#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{position:relative;width:100%;max-width:100%;margin:0 auto;padding:0 20px;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{width:100%;float:left;box-sizing:border-box;padding:0;display:initial}@media (min-width: 400px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:90%;padding:0}}@media (min-width: 550px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:100%}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{margin-left:4%}#onetrust-banner-sdk .ot-sdk-column:first-child,#onetrust-banner-sdk .ot-sdk-columns:first-child,#onetrust-pc-sdk .ot-sdk-column:first-child,#onetrust-pc-sdk .ot-sdk-columns:first-child,#ot-sdk-cookie-policy .ot-sdk-column:first-child,#ot-sdk-cookie-policy .ot-sdk-columns:first-child{margin-left:0}#onetrust-banner-sdk .ot-sdk-two.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-two.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-two.ot-sdk-columns{width:13.3333333333%}#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-three.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-three.ot-sdk-columns{width:22%}#onetrust-banner-sdk .ot-sdk-four.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-four.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-four.ot-sdk-columns{width:30.6666666667%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eight.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eight.ot-sdk-columns{width:65.3333333333%}#onetrust-banner-sdk .ot-sdk-nine.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-nine.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-nine.ot-sdk-columns{width:74%}#onetrust-banner-sdk .ot-sdk-ten.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-ten.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-ten.ot-sdk-columns{width:82.6666666667%}#onetrust-banner-sdk .ot-sdk-eleven.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eleven.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eleven.ot-sdk-columns{width:91.3333333333%}#onetrust-banner-sdk .ot-sdk-twelve.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-twelve.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-twelve.ot-sdk-columns{width:100%;margin-left:0}}#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6{margin-top:0;font-weight:600;font-family:inherit}#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem;line-height:1.2}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem;line-height:1.25}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem;line-height:1.3}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem;line-height:1.35}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem;line-height:1.5}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem;line-height:1.6}@media (min-width: 550px){#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem}}#onetrust-banner-sdk p,#onetrust-pc-sdk p,#ot-sdk-cookie-policy p{margin:0 0 1em 0;font-family:inherit;line-height:normal}#onetrust-banner-sdk a,#onetrust-pc-sdk a,#ot-sdk-cookie-policy a{color:#565656;text-decoration:underline}#onetrust-banner-sdk a:hover,#onetrust-pc-sdk a:hover,#ot-sdk-cookie-policy a:hover{color:#565656;text-decoration:none}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{display:inline-block;height:38px;padding:0 30px;color:#555;text-align:center;font-size:0.9em;font-weight:400;line-height:38px;letter-spacing:0.01em;text-decoration:none;white-space:nowrap;background-color:transparent;border-radius:2px;border:1px solid #bbb;cursor:pointer;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-button:hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#onetrust-pc-sdk .ot-sdk-button:hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#ot-sdk-cookie-policy .ot-sdk-button:hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus{color:#333;border-color:#888;opacity:0.7}#onetrust-banner-sdk .ot-sdk-button:focus,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:focus,#onetrust-pc-sdk .ot-sdk-button:focus,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:focus,#ot-sdk-cookie-policy .ot-sdk-button:focus,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:focus{outline:2px solid #000}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-banner-sdk button.ot-sdk-button-primary,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-pc-sdk button.ot-sdk-button-primary,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary,#ot-sdk-cookie-policy button.ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary{color:#fff;background-color:#33c3f0;border-color:#33c3f0}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-banner-sdk button.ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary:hover,#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-banner-sdk button.ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary:focus,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-pc-sdk button.ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary:hover,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-pc-sdk button.ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary:focus{color:#fff;background-color:#1eaedb;border-color:#1eaedb}#onetrust-banner-sdk input[type="text"],#onetrust-pc-sdk input[type="text"],#ot-sdk-cookie-policy input[type="text"]{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-banner-sdk input[type="text"],#onetrust-pc-sdk input[type="text"],#ot-sdk-cookie-policy input[type="text"]{-webkit-appearance:none;-moz-appearance:none;appearance:none}#onetrust-banner-sdk input[type="text"]:focus,#onetrust-pc-sdk input[type="text"]:focus,#ot-sdk-cookie-policy input[type="text"]:focus{border:1px solid #000;outline:0}#onetrust-banner-sdk label,#onetrust-pc-sdk label,#ot-sdk-cookie-policy label{display:block;margin-bottom:0.5rem;font-weight:600}#onetrust-banner-sdk input[type="checkbox"],#onetrust-pc-sdk input[type="checkbox"],#ot-sdk-cookie-policy input[type="checkbox"]{display:inline}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{list-style:circle inside}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{padding-left:0;margin-top:0}#onetrust-banner-sdk ul ul,#onetrust-pc-sdk ul ul,#ot-sdk-cookie-policy ul ul{margin:1.5rem 0 1.5rem 3rem;font-size:90%}#onetrust-banner-sdk li,#onetrust-pc-sdk li,#ot-sdk-cookie-policy li{margin-bottom:1rem}#onetrust-banner-sdk th,#onetrust-banner-sdk td,#onetrust-pc-sdk th,#onetrust-pc-sdk td,#ot-sdk-cookie-policy th,#ot-sdk-cookie-policy td{padding:12px 15px;text-align:left;border-bottom:1px solid #e1e1e1}#onetrust-banner-sdk button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-container:after,#onetrust-banner-sdk .ot-sdk-row:after,#onetrust-pc-sdk .ot-sdk-container:after,#onetrust-pc-sdk .ot-sdk-row:after,#ot-sdk-cookie-policy .ot-sdk-container:after,#ot-sdk-cookie-policy .ot-sdk-row:after{content:"";display:table;clear:both}#onetrust-banner-sdk .ot-sdk-row,#onetrust-pc-sdk .ot-sdk-row,#ot-sdk-cookie-policy .ot-sdk-row{margin:0;max-width:none;display:block}
#onetrust-banner-sdk.otFloatingRoundedIcon{position:fixed;bottom:2em;right:0;left:5em;z-index:2147483645;background-color:#fff;width:75%;border-radius:6.5px;padding:20px 0;-webkit-box-shadow:0 0 18px rgba(0,0,0,.2);-moz-box-shadow:0 0 18px rgba(0,0,0,.2);box-shadow:0 0 18px rgba(0,0,0,.2)}#onetrust-banner-sdk.otFloatingRoundedIcon.otRelFont{font-size:1rem}#onetrust-banner-sdk .banner-content{overflow-x:hidden;overflow-y:auto;max-height:85vh}#onetrust-banner-sdk .banner-content::-webkit-scrollbar{width:11px}#onetrust-banner-sdk .banner-content::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-banner-sdk .banner-content{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-banner-sdk h3{margin-bottom:0;font-size:1.7em}#onetrust-banner-sdk #onetrust-policy{margin-left:50px}#onetrust-banner-sdk #onetrust-policy .ot-gv-list-handler{float:left;font-size:.812em;padding:0;margin-bottom:0;border:0;height:auto;line-height:normal}#onetrust-banner-sdk #onetrust-button-group-parent{text-align:center}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler{background-color:#68b631;color:#fff;border-color:#68b631;margin-bottom:.6rem}#onetrust-banner-sdk #onetrust-pc-btn-handler{background-color:#68b631;color:#fff;border:1px solid #68b631;padding:0}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{border-radius:50px;font-weight:600;letter-spacing:.05em;min-width:160px;height:auto;white-space:normal;word-break:break-word;word-wrap:break-word;padding:10px 10px;line-height:1.6;-webkit-box-shadow:0px 2px 10px -3px #999;-moz-box-shadow:0px 2px 10px -3px #999;box-shadow:0px 2px 10px -3px #999}#onetrust-banner-sdk #onetrust-pc-btn-handler.cookie-setting-link{background-color:#fff;border:none;color:#68b631;text-decoration:underline;padding-left:0;padding-right:0;box-shadow:none}#onetrust-banner-sdk .onetrust-close-btn-ui{float:right;width:44px;height:44px;background-size:12px;margin:-5px 0 0 0;border:none;padding:0}#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:12px;right:0}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-b-addl-desc{clear:both;float:left;margin-bottom:0;padding-bottom:10px;font-size:.8em;line-height:1.5}#onetrust-banner-sdk #onetrust-policy-text>*,#onetrust-banner-sdk .ot-b-addl-desc>*{font-size:inherit}#onetrust-banner-sdk #onetrust-policy-text a,#onetrust-banner-sdk .ot-b-addl-desc a{font-weight:600;margin-left:5px}#onetrust-banner-sdk .ot-b-addl-desc{display:block}#onetrust-banner-sdk .ot-dpd-desc>.ot-b-addl-desc{padding:0;width:100%;font-size:1em;line-height:1.5;margin-top:10px;margin-bottom:10px}#onetrust-banner-sdk #onetrust-policy-title{float:left;text-align:left;font-size:1em;line-height:1.3;font-weight:600;margin-bottom:10px;color:#2c3643}#onetrust-banner-sdk #onetrust-policy-title a{color:#6c7985}#onetrust-banner-sdk #onetrust-policy-text a{font-weight:bold}#onetrust-banner-sdk #onetrust-cookie-btn{display:block;border-radius:50%;height:64px;width:64px;cursor:pointer;padding:0;margin-bottom:0;border:0}#onetrust-banner-sdk #onetrust-cookie-btn:focus,#onetrust-banner-sdk #onetrust-cookie-btn:hover{opacity:.7}#onetrust-banner-sdk #onetrust-cookie-btn-container{position:absolute;float:left;z-index:1;left:-35px;top:53%;transform:translateY(-50%)}#onetrust-banner-sdk .banner_logo{display:none}#onetrust-banner-sdk #banner-options{float:left;margin-left:50px;margin-top:10px;margin-bottom:1em}#onetrust-banner-sdk .banner-option-input{cursor:pointer;width:auto;height:auto;border:none;padding:0;padding-right:3px;margin-bottom:6px;margin-left:20px;font-size:.82em;line-height:1.4}#onetrust-banner-sdk .banner-option-input *{pointer-events:none;font-size:inherit;line-height:inherit}#onetrust-banner-sdk .banner-option-input[aria-expanded=true] .ot-arrow-container{transform:rotate(90deg)}#onetrust-banner-sdk #purpose-option[aria-expanded=true]~.banner-option-details.purpose-option,#onetrust-banner-sdk #feature-option[aria-expanded=true]~.banner-option-details.feature-option,#onetrust-banner-sdk #information-option[aria-expanded=true]~.banner-option-details.information-option{display:block;height:auto}#onetrust-banner-sdk .banner-option-header{cursor:pointer;display:inline-block}#onetrust-banner-sdk .banner-option-header :first-child{color:dimgray;font-weight:bold;float:left}#onetrust-banner-sdk .banner-option-header .ot-arrow-container{display:inline-block;border-top:6px solid transparent;border-bottom:6px solid transparent;border-left:6px solid dimgray;margin-left:10px;vertical-align:middle;transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .banner-option-details{display:none;font-size:.83em;line-height:1.5;height:0px;padding:10px 10px 5px 10px;transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .banner-option-details *{font-size:inherit;line-height:inherit;color:dimgray}#onetrust-banner-sdk .ot-dpd-container{float:left;clear:both}#onetrust-banner-sdk .ot-dpd-container .ot-dpd-title{font-weight:600;padding-bottom:8px}#onetrust-banner-sdk .ot-dpd-container .ot-dpd-desc,#onetrust-banner-sdk .ot-dpd-container .ot-dpd-title{font-size:.813em;line-height:1.5}#onetrust-banner-sdk .ot-dpd-container .ot-dpd-desc .onetrust-vendors-list-handler{display:block;margin-left:0px;margin-top:5px;clear:both;padding:0;margin-bottom:0;border:0;line-height:normal;height:auto;width:auto}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container{position:static;margin:0;text-align:center}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container button{white-space:pre-wrap;border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;min-width:175px;float:none;padding:0}#onetrust-banner-sdk.ot-close-btn-link.ot-wo-title #onetrust-group-container{margin-top:20px}@media(min-width: 550px){#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns{width:15%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns{width:74.333333%}}@media only screen and (min-width: 426px)and (max-width: 896px){#onetrust-banner-sdk{padding:20px 0 10px 0}#onetrust-banner-sdk #onetrust-policy,#onetrust-banner-sdk #onetrust-button-group-parent{margin-left:0}#onetrust-banner-sdk .ot-sdk-container .ot-sdk-row{margin:0 15px 0 15px}#onetrust-banner-sdk #onetrust-cookie-btn-container{display:none}#onetrust-banner-sdk #onetrust-accept-btn-container,#onetrust-banner-sdk #onetrust-reject-btn-container,#onetrust-banner-sdk #onetrust-pc-btn-container{display:inline-block;margin-top:15px}#onetrust-banner-sdk #onetrust-pc-btn-container{float:left;margin-right:1em}#onetrust-banner-sdk #onetrust-accept-btn-container{float:right}#onetrust-banner-sdk #onetrust-button-group{display:inline-block}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-b-addl-desc{font-size:.813em;width:94%}#onetrust-banner-sdk #onetrust-policy-text>*,#onetrust-banner-sdk .ot-b-addl-desc>*{font-size:inherit}#onetrust-banner-sdk #onetrust-accept-btn-container,#onetrust-banner-sdk #onetrust-reject-btn-container{margin-right:10px}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns{width:100%}#onetrust-banner-sdk #banner-options{margin-left:1em}#onetrust-banner-sdk.otFloatingRoundedIcon{left:0;bottom:0;border-radius:0;width:100%;padding:20px 0 10px 0}}@media only screen and (min-width: 769px){#onetrust-banner-sdk.otFloatingRoundedIcon[dir=rtl]{right:20%}}@media only screen and (min-width: 897px){#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;margin-top:10px;transform:translateY(-50%);width:20%;left:64%}#onetrust-banner-sdk #onetrust-group-container{width:64%}#onetrust-banner-sdk #banner-options{width:60%;margin:0;padding-left:50px}#onetrust-banner-sdk #onetrust-button-group-parent{width:20%;left:64%}}@media only screen and (min-width: 1024px){#onetrust-banner-sdk .banner-content{overflow-x:initial;overflow-y:initial;padding-bottom:20px;padding-top:20px}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-banner-sdk #onetrust-group-container{width:64%}#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{width:20%;left:66%}#onetrust-banner-sdk #onetrust-button-group-parent{width:20%;left:66%}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{width:auto}#onetrust-banner-sdk #onetrust-accept-btn-container,#onetrust-banner-sdk #onetrust-reject-btn-container,#onetrust-banner-sdk #onetrust-pc-btn-container{text-align:center}#onetrust-banner-sdk:not(.vertical-align-content){padding:0}#onetrust-banner-sdk:not(.vertical-align-content) #onetrust-button-group-parent{margin-left:66%}#onetrust-banner-sdk:not(.vertical-align-content) #onetrust-group-container{position:absolute;top:50%;transform:translateY(-50%);left:0}#onetrust-banner-sdk:not(.vertical-align-content) #onetrust-close-btn-container{margin-top:20px}#onetrust-banner-sdk #onetrust-accept-btn-container{margin-top:1em}#onetrust-banner-sdk #onetrust-close-btn-container{margin-right:20px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-button-group-parent{width:28%}#onetrust-banner-sdk.ot-close-btn-link #onetrust-accept-btn-container{margin-top:0}}@media only screen and (max-width: 768px){#onetrust-banner-sdk #banner-options{margin-left:0;padding:0;width:100%}#onetrust-banner-sdk #onetrust-button-group-parent:not(.has-reject-all-button) #onetrust-accept-btn-container{margin-right:0;width:100%}#onetrust-banner-sdk #onetrust-button-group-parent:not(.has-reject-all-button) #onetrust-accept-btn-container #onetrust-accept-btn-handler{width:100%}#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-accept-btn-container{margin-right:0;width:47%;float:right}#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-reject-btn-container{margin-right:0;width:47%}#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-reject-btn-container button{float:right}#onetrust-banner-sdk #onetrust-pc-btn-container{width:100%;text-align:center}}@media only screen and (max-width: 425px){#onetrust-banner-sdk #onetrust-policy{margin-left:0;margin-right:.2em}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-b-addl-desc{line-height:1.5;font-size:.813em;padding-top:2em}#onetrust-banner-sdk #onetrust-cookie-btn-container{display:none}#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-accept-btn-container,#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-reject-btn-container,#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-pc-btn-container,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-accept-btn-container,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-reject-btn-container,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-pc-btn-container{width:100%}#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-button-group-parent.has-reject-all-button #onetrust-pc-btn-handler,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-button-group-parent #onetrust-pc-btn-handler{width:100%;letter-spacing:0;font-size:.813em}#onetrust-banner-sdk #onetrust-policy-title{display:inline-block;line-height:1;margin-bottom:10px;width:95%}#onetrust-banner-sdk #onetrust-button-group-parent{margin-top:20px}#onetrust-banner-sdk #banner-options{margin-left:0;padding:0;width:100%}#onetrust-banner-sdk .onetrust-close-btn-ui{margin:-15px}#onetrust-banner-sdk #onetrust-group-container{margin-top:20px}#onetrust-banner-sdk #onetrust-close-btn-container{top:22px;right:22px}#onetrust-banner-sdk.otFloatingRoundedIcon{left:0;bottom:0;padding-bottom:0;padding-top:0;width:100%;border-radius:0}}
        #onetrust-consent-sdk #onetrust-banner-sdk {background-color: #FFFFFF;}
            #onetrust-consent-sdk #onetrust-policy-title,
                    #onetrust-consent-sdk #onetrust-policy-text,
                    #onetrust-consent-sdk .ot-b-addl-desc,
                    #onetrust-consent-sdk .ot-dpd-desc,
                    #onetrust-consent-sdk .ot-dpd-title,
                    #onetrust-consent-sdk #onetrust-policy-text *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk .ot-dpd-desc *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk #onetrust-banner-sdk #banner-options *,
                    #onetrust-banner-sdk .ot-cat-header {
                        color: #696969;
                    }
            #onetrust-consent-sdk #onetrust-banner-sdk .banner-option-details {
                    background-color: #E9E9E9;}
             #onetrust-consent-sdk #onetrust-banner-sdk a[href],
                    #onetrust-consent-sdk #onetrust-banner-sdk a[href] font,
                    #onetrust-consent-sdk #onetrust-banner-sdk .ot-link-btn
                        {
                            color: #3860BE;
                        }#onetrust-consent-sdk #onetrust-accept-btn-handler,
                         #onetrust-banner-sdk #onetrust-reject-all-handler {
                            background-color: #EA232B;border-color: #EA232B;
                color: #FFFFFF;
            }
            #onetrust-consent-sdk #onetrust-banner-sdk *:focus,
            #onetrust-consent-sdk #onetrust-banner-sdk:focus {
               outline-color: #000000;
               outline-width: 1px;
            }
            #onetrust-consent-sdk #onetrust-pc-btn-handler,
            #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link {
                color: #EA232B; border-color: #EA232B;
                background-color: 
                #FFFFFF;
            }@keyframes ot-slide-in-left{from{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0)}to{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0)}}@keyframes ot-slide-in-right{from{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0)}to{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0)}}@keyframes ot-slide-out-left{from{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0)}to{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0)}}@keyframes ot-slide-out-right{from{-webkit-transform:translate3d(0, 0, 0);transform:translate3d(0, 0, 0)}to{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0)}}#onetrust-pc-sdk.otPcPanel.ot-slide-out-right{-webkit-animation-name:ot-slide-out-right;animation-name:ot-slide-out-right}#onetrust-pc-sdk.otPcPanel.ot-slide-in-left{-webkit-animation-name:ot-slide-in-left;animation-name:ot-slide-in-left}#onetrust-pc-sdk.otPcPanel.ot-slide-in-right{-webkit-animation-name:ot-slide-in-right;animation-name:ot-slide-in-right}#onetrust-pc-sdk.otPcPanel.ot-slide-out-left{-webkit-animation-name:ot-slide-out-left;animation-name:ot-slide-out-left}@media print,(prefers-reduced-motion){.ot-animated{-webkit-animation:initial !important;animation:initial !important;-webkit-transition:none !important;transition:none !important}#onetrust-pc-sdk.otPcPanel.ot-slide-out-left{-webkit-transform:translate3d(-100%, 0, 0);transform:translate3d(-100%, 0, 0)}#onetrust-pc-sdk.otPcPanel.ot-slide-out-right{-webkit-transform:translate3d(100%, 0, 0);transform:translate3d(100%, 0, 0)}}#onetrust-pc-sdk{position:fixed;z-index:2147483647;bottom:0;left:0;background-color:#fff;max-width:480px;min-width:480px;height:100%;-webkit-box-shadow:0px 2px 10px -3px #999;-moz-box-shadow:0px 2px 10px -3px #999;box-shadow:0px 2px 10px -3px #999}#onetrust-pc-sdk.otRelFont{font-size:1rem}#onetrust-pc-sdk.otPcPanel.right,#onetrust-pc-sdk.otPcPanel[dir=rtl]{right:0;left:auto}#onetrust-pc-sdk.otPcPanel.right-rtl[dir=rtl]{left:0;right:auto}#onetrust-pc-sdk.otPcPanel.ot-animated{-webkit-animation-duration:1s;animation-duration:1s;-webkit-animation-fill-mode:both;animation-fill-mode:both}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon{background-color:transparent;border:none}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-track{margin-right:20px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar{width:11px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-thumb{border-radius:10px;background:#d8d8d8}#onetrust-pc-sdk .ot-pc-scrollbar{scrollbar-arrow-color:#d8d8d8;scrollbar-darkshadow-color:#d8d8d8;scrollbar-face-color:#d8d8d8;scrollbar-shadow-color:#d8d8d8}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-refuse-all-handler{margin-bottom:0px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:160px}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-footer button{width:100%;max-width:none}#onetrust-pc-sdk.ot-ftr-stacked #ot-lst-cnt{max-height:84%}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus,#onetrust-pc-sdk .ot-hide-tgl{visibility:hidden}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr *,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus *,#onetrust-pc-sdk .ot-hide-tgl *{visibility:hidden}#onetrust-pc-sdk .ot-pc-header{height:39px;border-bottom:1px solid #e9e9e9;padding:10px 0 10px 25px}#onetrust-pc-sdk .ot-pc-logo{height:40px;width:120px;display:inline-block}#onetrust-pc-sdk .ot-close-icon{float:right;height:10px;width:10px;margin-top:10px;margin-right:5px}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{position:absolute;top:60px;bottom:104px}#onetrust-pc-sdk #ot-pc-content{padding-left:2px;padding-right:10px;margin-left:23px;margin-right:7px;width:calc(100% - 42px);overflow-y:auto}#onetrust-pc-sdk #ot-pc-lst{width:100%}#onetrust-pc-sdk .ot-pc-footer{position:absolute;bottom:0px;width:100%;max-height:160px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-pc-footer button{margin-top:19px}#onetrust-pc-sdk .ot-btn-container{text-align:left;margin-left:25px;margin-right:25px}#onetrust-pc-sdk .ot-btn-container button{min-width:calc(50% - 5px)}#onetrust-pc-sdk .ot-pc-footer-logo{padding-left:25px;height:30px;background:#f4f4f4;text-align:right}#onetrust-pc-sdk .ot-pc-footer-logo a{display:inline-block;margin-top:5px;margin-right:10px}#onetrust-pc-sdk.otPcPanel[dir=rtl] .ot-pc-footer-logo{direction:rtl}#onetrust-pc-sdk.otPcPanel[dir=rtl] .ot-pc-footer-logo a{margin-right:25px}#onetrust-pc-sdk button{display:inline-block;font-size:.75em;letter-spacing:.08em;max-width:394px;padding:12px 30px;line-height:1;word-break:break-word;word-wrap:break-word;white-space:normal;font-weight:bold;height:auto}#onetrust-pc-sdk button:hover,#onetrust-pc-sdk button:focus{color:#fff;border-color:#68b631}#onetrust-pc-sdk .ot-link-btn{padding:0;margin-bottom:0;border:0;font-weight:normal;line-height:normal;width:auto;height:auto}#onetrust-pc-sdk #accept-recommended-btn-handler{margin-right:10px;margin-bottom:25px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-right:5px}#onetrust-pc-sdk .ot-tgl{float:right;position:relative;z-index:1}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background-color:#d5e9ff;border:1px solid #3860be}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{-webkit-transform:translateX(21px);-ms-transform:translateX(21px);transform:translateX(21px);background-color:#3860be}#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0 1px #2196f3;outline-style:auto !important;outline-width:1px !important}#onetrust-pc-sdk .ot-switch{position:relative;display:inline-block;width:45px;height:25px;margin-bottom:0}#onetrust-pc-sdk .ot-switch-nob{position:absolute;cursor:pointer;top:0;left:0;right:0;bottom:0;background-color:#f2f1f1;border:1px solid #ddd;transition:all .2s ease-in 0s;-moz-transition:all .2s ease-in 0s;-o-transition:all .2s ease-in 0s;-webkit-transition:all .2s ease-in 0s;border-radius:20px}#onetrust-pc-sdk .ot-switch-nob:before{position:absolute;content:"";height:21px;width:21px;bottom:1px;background-color:#7d7d7d;-webkit-transition:.4s;transition:.4s;border-radius:20px}#onetrust-pc-sdk .ot-chkbox{z-index:1}#onetrust-pc-sdk .ot-chkbox input:checked~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk .ot-chkbox label{position:relative;display:inline-block;cursor:pointer}#onetrust-pc-sdk .ot-chkbox label::before,#onetrust-pc-sdk .ot-chkbox label::after{position:absolute;content:"";display:inline-block;border-radius:3px}#onetrust-pc-sdk .ot-chkbox label::before{height:18px;width:18px;border:1px solid #3860be;left:0px}#onetrust-pc-sdk .ot-chkbox label::after{height:5px;width:9px;border-left:3px solid;border-bottom:3px solid;transform:rotate(-45deg);-o-transform:rotate(-45deg);-ms-transform:rotate(-45deg);-webkit-transform:rotate(-45deg);left:4px;top:5px}#onetrust-pc-sdk .ot-label-txt{display:none}#onetrust-pc-sdk .ot-chkbox input,#onetrust-pc-sdk .ot-tgl input{position:absolute;opacity:0;width:0;height:0}#onetrust-pc-sdk .ot-arw-cntr{left:5px;float:right;position:relative;pointer-events:none}#onetrust-pc-sdk .ot-arw{width:16px;height:16px;margin-left:5px;color:dimgray;display:inline-block;vertical-align:middle;-webkit-transition:all 150ms ease-in 0s;-moz-transition:all 150ms ease-in 0s;-o-transition:all 150ms ease-in 0s;transition:all 150ms ease-in 0s}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw-cntr svg{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:1px solid #000}#onetrust-pc-sdk .ot-acc-hdr{display:inline-block;width:100%}#onetrust-pc-sdk #ot-fltr-modal .ot-label-txt{display:inline-block;font-size:.85em;color:dimgray}#onetrust-pc-sdk .ot-label-status{padding-left:5px;font-size:.75em;display:none}#onetrust-pc-sdk .ot-plus-minus{width:20px;height:20px;font-size:1.5em;position:relative;display:inline-block;margin-right:5px;top:3px}#onetrust-pc-sdk .ot-plus-minus span{position:absolute;background:#27455c;border-radius:1px}#onetrust-pc-sdk .ot-plus-minus span:first-of-type{top:25%;bottom:25%;width:10%;left:45%}#onetrust-pc-sdk .ot-plus-minus span:last-of-type{left:25%;right:25%;height:10%;top:45%}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:first-of-type,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{transform:rotate(90deg)}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{left:50%;right:50%}#onetrust-pc-sdk .ot-host-item,#onetrust-pc-sdk .ot-ven-item{padding-right:0}#onetrust-pc-sdk .ot-host-item .ot-plus-minus,#onetrust-pc-sdk .ot-ven-item .ot-plus-minus{float:left;margin-right:8px;margin-top:10px}#onetrust-pc-sdk .ot-ven-item ul{list-style:none inside;font-size:100%;margin:0}#onetrust-pc-sdk .ot-ven-item ul li{margin:0 !important;padding:0;border:none !important}#onetrust-pc-sdk .ot-hide-acc>button{pointer-events:none}#onetrust-pc-sdk .ot-hide-acc .ot-plus-minus>*,#onetrust-pc-sdk .ot-hide-acc .ot-arw-cntr>*{visibility:hidden}#onetrust-pc-sdk .ot-hide-acc .ot-acc-hdr{min-height:30px}#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-pc-desc,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk .ot-cat-item p:last-of-type{color:dimgray}#onetrust-pc-sdk #ot-pc-title{margin-top:20px;margin-bottom:10px}#onetrust-pc-sdk #ot-pc-desc,#onetrust-pc-sdk .ot-cat-item p{font-size:.79em;line-height:1.4}#onetrust-pc-sdk #ot-pc-desc *,#onetrust-pc-sdk .ot-cat-item p *{font-size:inherit;line-height:inherit}#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk #ot-pc-title{font-size:1.125em;line-height:1.2}#onetrust-pc-sdk #ot-pc-desc{clear:both;font-size:.813em;line-height:1.5;margin-bottom:25px}#onetrust-pc-sdk #ot-pc-desc *{font-size:inherit}#onetrust-pc-sdk #ot-pc-desc a{display:block;margin-top:5px;margin-bottom:5px}#onetrust-pc-sdk #ot-pc-desc li{padding:10px 0px}#onetrust-pc-sdk #ot-pc-desc,#onetrust-pc-sdk #accept-recommended-btn-handler,#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header{float:left}#onetrust-pc-sdk #ot-category-title{width:100%;text-align:left}#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk #ot-lst-title,#onetrust-pc-sdk .ot-ven-hdr .ot-ven-name,#onetrust-pc-sdk .ot-always-active{font-weight:bold}#onetrust-pc-sdk a{color:#656565;cursor:pointer}#onetrust-pc-sdk a:hover{color:#3860be}#onetrust-pc-sdk .ot-always-active{float:right;color:#3860be;margin-top:-2px}#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk .ot-always-active{font-size:.88em;line-height:1.4;position:relative}#onetrust-pc-sdk .ot-cat-item{margin-top:25px;line-height:1.1}#onetrust-pc-sdk .ot-cat-item p:last-of-type{clear:both;padding-top:15px;margin:0}#onetrust-pc-sdk .ot-acc-txt p ul,#onetrust-pc-sdk .ot-cat-item ul,#onetrust-pc-sdk li.ot-subgrp p ul{margin:0px;list-style:disc;margin-left:15px}#onetrust-pc-sdk .ot-acc-txt p ul li,#onetrust-pc-sdk .ot-cat-item ul li,#onetrust-pc-sdk li.ot-subgrp p ul li{font-size:inherit;margin:5px 0 0 0;padding:0;border:none}#onetrust-pc-sdk .ot-subgrp-cntr{display:inline-block;width:100%}#onetrust-pc-sdk .ot-subgrp-cntr .ot-tgl-cntr{float:right}#onetrust-pc-sdk .ot-subgrp-cntr .ot-tgl-cntr.ot-always-active-subgroup{width:auto}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li p,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li h5{font-size:.813em;line-height:1.5;color:dimgray}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr{display:inline-block;width:100%;vertical-align:middle}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-txt{margin:0}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li{margin:10px 0 0 0;padding:0;border:none}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li p{clear:both;float:left;padding-top:10px;margin:0}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li h5{font-weight:bold;margin-bottom:0;float:left;position:relative;top:6px}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp{margin-left:20px;overflow:hidden}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp>p ul:first-child{padding-bottom:7.5px}#onetrust-pc-sdk ul.ot-subgrps{margin:0}#onetrust-pc-sdk .ot-hlst-cntr,#onetrust-pc-sdk .ot-vlst-cntr{margin-top:3px;overflow:hidden;clear:both;padding-left:2px;padding-bottom:2px}#onetrust-pc-sdk .ot-always-active-subgroup{width:auto;padding-left:0px !important;top:3px;position:relative}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{color:#3860be;margin-left:0;font-size:.813em;text-decoration:none;float:left;margin-top:5px}#onetrust-pc-sdk .category-vendors-list-handler:hover,#onetrust-pc-sdk .category-vendors-list-handler+a:hover,#onetrust-pc-sdk .category-host-list-handler:hover{text-decoration-line:underline}#onetrust-pc-sdk .category-vendors-list-handler+a{clear:none}#onetrust-pc-sdk .category-vendors-list-handler+a::after{content:"";height:15px;width:15px;background-repeat:no-repeat;margin-left:5px;float:right;background-image:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 511.626 511.627'%3E%3Cg fill='%231276CE'%3E%3Cpath d='M392.857 292.354h-18.274c-2.669 0-4.859.855-6.563 2.573-1.718 1.708-2.573 3.897-2.573 6.563v91.361c0 12.563-4.47 23.315-13.415 32.262-8.945 8.945-19.701 13.414-32.264 13.414H82.224c-12.562 0-23.317-4.469-32.264-13.414-8.945-8.946-13.417-19.698-13.417-32.262V155.31c0-12.562 4.471-23.313 13.417-32.259 8.947-8.947 19.702-13.418 32.264-13.418h200.994c2.669 0 4.859-.859 6.57-2.57 1.711-1.713 2.566-3.9 2.566-6.567V82.221c0-2.662-.855-4.853-2.566-6.563-1.711-1.713-3.901-2.568-6.57-2.568H82.224c-22.648 0-42.016 8.042-58.102 24.125C8.042 113.297 0 132.665 0 155.313v237.542c0 22.647 8.042 42.018 24.123 58.095 16.086 16.084 35.454 24.13 58.102 24.13h237.543c22.647 0 42.017-8.046 58.101-24.13 16.085-16.077 24.127-35.447 24.127-58.095v-91.358c0-2.669-.856-4.859-2.574-6.57-1.713-1.718-3.903-2.573-6.565-2.573z'/%3E%3Cpath d='M506.199 41.971c-3.617-3.617-7.905-5.424-12.85-5.424H347.171c-4.948 0-9.233 1.807-12.847 5.424-3.617 3.615-5.428 7.898-5.428 12.847s1.811 9.233 5.428 12.85l50.247 50.248-186.147 186.151c-1.906 1.903-2.856 4.093-2.856 6.563 0 2.479.953 4.668 2.856 6.571l32.548 32.544c1.903 1.903 4.093 2.852 6.567 2.852s4.665-.948 6.567-2.852l186.148-186.148 50.251 50.248c3.614 3.617 7.898 5.426 12.847 5.426s9.233-1.809 12.851-5.426c3.617-3.616 5.424-7.898 5.424-12.847V54.818c-.001-4.952-1.814-9.232-5.428-12.847z'/%3E%3C/g%3E%3C/svg%3E")}#onetrust-pc-sdk .back-btn-handler{min-height:20px;font-size:1em;text-decoration:none}#onetrust-pc-sdk .back-btn-handler svg{width:12px;height:12px}#onetrust-pc-sdk .back-btn-handler:hover{opacity:.6}#onetrust-pc-sdk #ot-lst-title h3{word-break:break-word;word-wrap:break-word;margin-bottom:0;color:#656565;font-weight:bold;margin-left:15px;display:inline-block;font-size:1em}#onetrust-pc-sdk #ot-lst-title{margin-top:15px;font-size:1em}#onetrust-pc-sdk #ot-pc-hdr{display:inline-block;padding-left:27px;padding-right:17px;width:calc(100% - 44px)}#onetrust-pc-sdk #ot-pc-hdr input::placeholder{color:#d4d4d4;font-style:italic}#onetrust-pc-sdk #vendor-search-handler{height:31px;width:100%;border-radius:50px;font-size:.8em;padding-right:35px;padding-left:15px;float:left;margin-left:15px}#onetrust-pc-sdk #ot-lst-cnt{transform:translate3d(0, 0, 0);position:relative;padding-left:27px;margin-right:10px;margin-top:10px;width:calc(100% - 37px);top:0;bottom:70px;height:calc(100% - 94px);overflow-y:auto;overflow-x:hidden}#onetrust-pc-sdk #ot-pc-lst .ot-tgl-cntr{right:32px;position:absolute;margin-top:10px;height:20px}#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr):not(.ot-hosts-ui) .ot-tgl-cntr{right:12px}#onetrust-pc-sdk #ot-sel-blk{position:sticky;position:-webkit-sticky;width:100%;display:inline-block;top:0;overflow:hidden;z-index:3}#onetrust-pc-sdk #ot-sel-blk p{font-size:.75em;color:#6b6b6b;margin:0;display:inline-block}#onetrust-pc-sdk .ot-enbl-chr>:not(.ot-hosts-ui) .ot-sel-all{padding-right:33px}#onetrust-pc-sdk .ot-enbl-chr .ot-hosts-ui .ot-sel-all{padding-right:23px}#onetrust-pc-sdk .ot-enbl-chr .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:105px}#onetrust-pc-sdk .ot-enbl-chr .ot-cat-item h5+.ot-tgl-cntr{padding-left:31px;padding-right:13px}#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr *{visibility:hidden}#onetrust-pc-sdk #ot-pc-content:not(.ot-enbl-chr) .ot-pli-hdr.ot-leg-border-color span:first-child{text-align:center}#onetrust-pc-sdk #ot-pc-content:not(.ot-enbl-chr) .ot-pli-hdr.ot-leg-border-color span:last-child{text-align:right}#onetrust-pc-sdk .ot-hosts-ui:not(.ot-enbl-chr) .ot-tgl-cntr{right:23px}#onetrust-pc-sdk .ot-hosts-ui #ot-sel-blk{width:100%}#onetrust-pc-sdk .ot-lst-subhdr{display:inline-block;width:100%;margin-top:10px}#onetrust-pc-sdk .ot-lst-subhdr svg{width:30px;height:30px;position:absolute;float:left;right:-15px}#onetrust-pc-sdk .ot-search-cntr{float:left;width:82%;position:relative}#onetrust-pc-sdk .ot-fltr-cntr{float:right;right:15px;position:relative}#onetrust-pc-sdk #filter-btn-handler{background-color:#3860be;border-radius:17px;display:inline-block;position:relative;width:32px;height:32px;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease;padding:0;margin:0}#onetrust-pc-sdk #filter-btn-handler:hover{opacity:.7}#onetrust-pc-sdk #filter-btn-handler svg{width:12px;margin:6px 10px 0 9px;display:block;height:12px;position:static;right:auto;top:auto}#onetrust-pc-sdk .ot-ven-link{color:#3860be;text-decoration:none;display:inline-block;margin-top:10px;transform:translate(0, 1%);-o-transform:translate(0, 1%);-ms-transform:translate(0, 1%);-webkit-transform:translate(0, 1%);z-index:2;position:relative;font-size:.75em}#onetrust-pc-sdk .ot-ven-link:hover{text-decoration:underline}#onetrust-pc-sdk .ot-ven-link *{font-size:inherit}#onetrust-pc-sdk .ot-ven-name{vertical-align:middle}#onetrust-pc-sdk .ot-ven-hdr,#onetrust-pc-sdk .ot-host-hdr{width:calc(100% - 165px);height:auto;float:left;text-align:left;word-break:break-word;word-wrap:break-word;vertical-align:middle;padding-bottom:2px;padding-left:2px}#onetrust-pc-sdk .ot-host-hdr{pointer-events:none;position:relative;z-index:1}#onetrust-pc-sdk .ot-host-hdr .ot-host-name{pointer-events:none}#onetrust-pc-sdk .ot-host-hdr a{pointer-events:initial}#onetrust-pc-sdk #ot-host-lst .ot-host-info{font-size:.7em;line-height:1.1}#onetrust-pc-sdk #ot-host-lst .ot-host-name,#onetrust-pc-sdk #ot-host-lst .ot-host-name a{color:dimgray;font-size:.81em;font-weight:bold;line-height:1.4;margin-bottom:5px;position:relative}#onetrust-pc-sdk #ot-host-lst .ot-host-name a,#onetrust-pc-sdk #ot-host-lst .ot-host-info a{font-size:1em}#onetrust-pc-sdk #ot-host-lst .ot-host-desc{width:100%;margin-bottom:5px}#onetrust-pc-sdk #ot-host-lst .ot-host-expand,#onetrust-pc-sdk #ot-host-lst .ot-host-desc{color:dimgray;font-size:.69em;line-height:1.4;float:left;font-weight:normal}#onetrust-pc-sdk #ot-host-lst .ot-host-hdr>a{text-decoration:underline;font-size:.69em;position:relative;z-index:2;float:left;margin-bottom:5px;line-height:1.4}#onetrust-pc-sdk #ot-host-lst .ot-host-expand{color:#3860be}#onetrust-pc-sdk #ot-host-lst .ot-host-expand *{font-size:inherit}#onetrust-pc-sdk .ot-host-opt{margin:0;font-size:inherit;display:inline-block;width:100%}#onetrust-pc-sdk .ot-host-opt .ot-host-info{border:none;font-size:.8em;color:dimgray;display:inline-block;width:calc(100% - 20px);padding:10px;margin-bottom:10px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-host-opt .ot-host-info>div{overflow:auto}#onetrust-pc-sdk .ot-host-opt li>div div{font-size:.8em;padding:5px 0}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(1){width:30%;float:left}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(2){width:70%;float:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #ot-ven-lst .ot-acc-hdr{overflow:hidden;cursor:pointer}#onetrust-pc-sdk .ot-ven-dets{border-radius:2px;margin-top:10px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-ven-dets li:first-child p:first-child{border-top:none}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:not(:first-child){border-top:1px solid #e9e9e9}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(odd){width:30%}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(even){width:50%;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p,#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h4{padding-top:5px;padding-bottom:5px;display:block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h4{display:inline-block}#onetrust-pc-sdk .ot-ven-dets p,#onetrust-pc-sdk .ot-ven-dets h4,#onetrust-pc-sdk .ot-ven-dets span{font-size:.69em;text-align:left;vertical-align:middle;word-break:break-word;word-wrap:break-word;margin:0;padding-bottom:10px;padding-left:15px;color:#2e3644}#onetrust-pc-sdk .ot-ven-dets h4{padding-top:5px}#onetrust-pc-sdk .ot-ven-dets span{color:dimgray;padding:0;vertical-align:baseline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-pur h4{border-top:1px solid #e9e9e9;border-bottom:1px solid #e9e9e9;padding-bottom:5px;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk #no-results{text-align:center;margin-top:30px;height:calc(100% - 300px);margin-left:27px}#onetrust-pc-sdk #no-results span{font-weight:bold}#onetrust-pc-sdk #no-results p{font-size:1em;color:#2e3644;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #ot-fltr-modal{right:13px;top:87px;height:90%;max-height:370px;display:none;-moz-transition:.2s ease;-o-transition:.2s ease;-webkit-transition:2s ease;transition:.2s ease;opacity:1;position:absolute}#onetrust-pc-sdk #ot-fltr-cnt{z-index:2147483646;background-color:#fff;position:relative;height:100%;max-width:325px;border-radius:3px;padding-right:10px;padding-bottom:5px;-webkit-box-shadow:0px 0px 12px 2px #c7c5c7;-moz-box-shadow:0px 0px 12px 2px #c7c5c7;box-shadow:0px 0px 12px 2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-scrlcnt{overflow-y:auto;overflow-x:hidden;clear:both;max-height:calc(100% - 60px)}#onetrust-pc-sdk #ot-anchor{border:12px solid transparent;display:none;position:absolute;z-index:2147483647;right:36px;top:75px;transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);-webkit-transform:rotate(45deg);background-color:#fff;-webkit-box-shadow:-3px -3px 5px -2px #c7c5c7;-moz-box-shadow:-3px -3px 5px -2px #c7c5c7;box-shadow:-3px -3px 5px -2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-btns{margin-left:15px}#onetrust-pc-sdk #filter-apply-handler{margin-right:15px}#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:20px;margin-left:15px;width:75%}#onetrust-pc-sdk .ot-fltr-opt label{padding-left:30px}#onetrust-pc-sdk .ot-fltr-opt p{display:inline-block;margin:0;font-size:.9em;color:#2e3644}#onetrust-pc-sdk #ot-sel-blk .ot-chkbox{width:20px;height:20px;float:right}#onetrust-pc-sdk .line-through label::after,#onetrust-pc-sdk[dir=rtl] .line-through label::after{height:auto;border-left:0;transform:none;-o-transform:none;-ms-transform:none;-webkit-transform:none;left:5px;top:8px}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label,#onetrust-pc-sdk #ot-selall-gnvencntr label{position:relative;display:inline-block;width:20px;height:20px;margin:0}#onetrust-pc-sdk #ot-selall-vencntr input,#onetrust-pc-sdk #ot-selall-adtlvencntr input,#onetrust-pc-sdk #ot-selall-hostcntr input,#onetrust-pc-sdk #ot-selall-licntr input,#onetrust-pc-sdk #ot-selall-gnvencntr input{height:auto;width:auto;border-radius:0;font-size:initial;padding:0;float:none}#onetrust-pc-sdk #ot-ven-lst:first-child{border-top:1px solid #e2e2e2}#onetrust-pc-sdk #vdr-lst-dsc{font-size:.812em;line-height:1.5;padding:10px 15px 5px 15px}#onetrust-pc-sdk #close-pc-btn-handler{margin:0;float:right;height:44px;width:44px;background-size:10px}#onetrust-pc-sdk #close-pc-btn-handler svg{display:block}#onetrust-pc-sdk .ot-close-icon{padding:0;background-color:transparent;border:none}#onetrust-pc-sdk #clear-filters-handler{float:right;max-width:200px;margin-bottom:10px;text-decoration:none;margin-top:20px;font-weight:bold;color:#3860be;font-size:.9em;letter-spacing:normal;border:none;padding:1px}#onetrust-pc-sdk #clear-filters-handler:hover{color:#2285f7}#onetrust-pc-sdk #clear-filters-handler:focus{outline:#000 solid 1px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:1px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;float:left;width:calc(100% - 2px)}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-vlst-cntr:first-child{margin-top:15px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc{font-size:.813em;line-height:1.5;padding-left:20px;padding-right:20px;width:calc(100% - 40px)}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc ul{padding-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:15px;width:calc(100% - 35px);display:inline-block;position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0px}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc+.ot-leg-btn-container{padding-left:20px;padding-right:16px;width:calc(100% - 36px)}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc+.ot-leg-btn-container{margin-top:5px;margin-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout input[type=checkbox]:checked~.ot-acc-txt.ot-acc-grpcntr{width:auto;padding-bottom:15px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;font-size:.88em;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;vertical-align:middle;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{right:16px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:88px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{right:10px;margin-top:-2px;left:auto}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active,#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%)}#onetrust-pc-sdk #ot-category-title{padding-bottom:10px}#onetrust-pc-sdk .ot-pli-hdr{color:#77808e;overflow:hidden;padding-top:7.5px;padding-bottom:7.5px;width:calc(100% - 2px);border-top-left-radius:3px;border-top-right-radius:3px}#onetrust-pc-sdk .ot-pli-hdr .ot-li-title{float:right;font-size:.813em}#onetrust-pc-sdk .ot-pli-hdr span:first-child{top:50%;transform:translateY(50%);max-width:80px}#onetrust-pc-sdk .ot-pli-hdr span:last-child{text-align:center;max-width:95px}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color{background-color:#f8f8f8;border:1px solid #e9e9e9}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color span:first-child{text-align:left;width:80px}#onetrust-pc-sdk .ot-subgrp>h5,#onetrust-pc-sdk .ot-cat-header{width:calc(100% - 130px);max-width:60%}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-subgrp>h5,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header{width:calc(100% - 145px)}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item h5+.ot-tgl-cntr,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header+.ot-tgl{padding-left:28px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-acc-grpdesc{margin-bottom:5px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border-top:1px solid #e9e9e9}#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr ul.ot-subgrps li{margin-top:5px;margin-bottom:5px}#onetrust-pc-sdk .ot-acc-hdr .ot-arw-cntr+.ot-tgl,#onetrust-pc-sdk .ot-cat-item h4+.ot-tgl,#onetrust-pc-sdk .ot-acc-txt h4+.ot-tgl-cntr{padding-left:30px}#onetrust-pc-sdk .ot-sel-all-hdr,#onetrust-pc-sdk .ot-sel-all-chkbox{position:relative;display:inline-block;width:100%}#onetrust-pc-sdk .ot-sel-all-chkbox{z-index:1}#onetrust-pc-sdk .ot-li-hdr,#onetrust-pc-sdk .ot-consent-hdr{float:right;font-size:.813em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-li-hdr{max-width:100px;min-width:100px}#onetrust-pc-sdk .ot-consent-hdr{margin-right:5px;max-width:55px}#onetrust-pc-sdk .ot-ven-litgl+.ot-arw-cntr{margin-left:81px}#onetrust-pc-sdk .ot-sel-all{margin:0;position:relative;padding-right:13px;float:right}#onetrust-pc-sdk #ot-selall-hostcntr,#onetrust-pc-sdk #ot-selall-vencntr{right:20px;position:relative}#onetrust-pc-sdk #ot-selall-licntr{position:relative;right:79px}#onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .ot-sel-all{position:relative;display:inline-block;width:20px;height:25px}#onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .ot-sel-all label{position:absolute;padding:0;width:18px;height:18px}#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:55%}#onetrust-pc-sdk .ot-leg-btn-container{display:inline-block;width:100%;margin-top:10px}#onetrust-pc-sdk .ot-leg-btn-container button{height:auto;padding:6.5px 8px;margin-bottom:0;letter-spacing:0;line-height:normal}#onetrust-pc-sdk .ot-leg-btn-container svg{display:none;height:14px;width:14px;padding-right:5px;vertical-align:sub}#onetrust-pc-sdk .ot-active-leg-btn{cursor:default;pointer-events:none}#onetrust-pc-sdk .ot-active-leg-btn svg{display:inline-block}#onetrust-pc-sdk .ot-remove-objection-handler{border:none;text-decoration:underline;padding:0;font-size:.82em;font-weight:600;line-height:1.4;padding-left:10px}#onetrust-pc-sdk .ot-obj-leg-btn-handler span{font-weight:bold;text-align:center;font-size:.91em;line-height:1.5}#onetrust-pc-sdk[dir=rtl] input~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk[dir=rtl] #ot-back-arw{transform:rotate(180deg);-o-transform:rotate(180deg);-ms-transform:rotate(180deg);-webkit-transform:rotate(180deg)}#onetrust-pc-sdk[dir=rtl] input:checked~.ot-acc-hdr .ot-arw{transform:rotate(270deg);-o-transform:rotate(270deg);-ms-transform:rotate(270deg);-webkit-transform:rotate(270deg)}#onetrust-pc-sdk[dir=rtl] .ot-chkbox label::after{transform:rotate(45deg);-webkit-transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);border-left:0;border-right:3px solid}#onetrust-pc-sdk[dir=rtl] .ot-lst-subhdr svg{right:0}#onetrust-pc-sdk .ot-ven-ctgl,#onetrust-pc-sdk .ot-ven-litgl,#onetrust-pc-sdk .ot-host-tgl,#onetrust-pc-sdk .ot-ven-gvctgl{position:relative;display:inline-block;width:20px;height:20px;margin-left:60px}#onetrust-pc-sdk .ot-ven-ctgl label,#onetrust-pc-sdk .ot-ven-litgl label,#onetrust-pc-sdk .ot-host-tgl label,#onetrust-pc-sdk .ot-ven-gvctgl label{position:absolute;width:20px;height:20px;margin:0}#onetrust-pc-sdk #ot-host-lst .ot-host-expand{clear:both;float:none;display:block}#onetrust-pc-sdk ul{list-style:none}#onetrust-pc-sdk ul li{position:relative;margin:0;padding:15px 15px 15px 15px;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk ul li h3{font-size:.75em;color:#656565;margin:0;height:auto;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk ul li p{margin:0;font-size:.7em}#onetrust-pc-sdk .ot-ven-item>button:focus,#onetrust-pc-sdk .ot-host-item>button:focus,#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button:focus,#onetrust-pc-sdk .ot-acc-cntr>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-ven-item>button,#onetrust-pc-sdk .ot-host-item>button,#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button,#onetrust-pc-sdk .ot-acc-cntr>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-ven-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-host-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-ven-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-host-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;width:auto;overflow:auto;display:block}#onetrust-pc-sdk .ot-host-item>button:focus{outline:0;border:2px solid #000}#onetrust-pc-sdk.ot-addtl-vendors .ot-enbl-chr #ot-selall-vencntr{right:0}#onetrust-pc-sdk.ot-addtl-vendors>:not(.ot-enbl-chr) #ot-selall-licntr{right:135px}#onetrust-pc-sdk.ot-addtl-vendors>:not(.ot-enbl-chr) #ot-selall-adtlvencntr,#onetrust-pc-sdk.ot-addtl-vendors>:not(.ot-enbl-chr) #ot-selall-gnvencntr{right:40px}#onetrust-pc-sdk.ot-addtl-vendors .ot-li-hdr{margin-right:15px}#onetrust-pc-sdk.ot-addtl-vendors #ot-selall-licntr{right:115px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk{background-color:#f9f9fc;border:1px solid #e2e2e2;width:auto;padding-bottom:5px;padding-top:5px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all{padding-right:23px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) ul li{border:1px solid #e2e2e2;margin-bottom:10px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-chkbox{float:right;width:auto;right:3px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-tgl-cntr{right:12px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-ven-ctgl{margin-left:75px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-ven-litgl+.ot-arw-cntr{margin-left:95px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-acc-cntr>.ot-acc-hdr{padding-top:10px;padding-bottom:10px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-addtl-venlst .ot-tgl-cntr{right:32px}#onetrust-pc-sdk.ot-addtl-vendors #ot-ven-lst:first-child{border-top:none}#onetrust-pc-sdk.ot-addtl-vendors #ot-selall-vencntr{right:40px;position:absolute}#onetrust-pc-sdk #ot-selall-adtlvencntr,#onetrust-pc-sdk #ot-selall-gnvencntr{position:relative;right:20px}#onetrust-pc-sdk .ot-acc-cntr{position:relative;border-left:1px solid #e2e2e2;border-right:1px solid #e2e2e2;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr{background-color:#f9f9fc;padding-left:15px;padding-top:5px;padding-bottom:5px;width:calc(100% - 15px)}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-plus-minus{vertical-align:middle;top:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-arw-cntr{right:10px;left:auto}#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-txt{padding-left:10px;padding-right:10px;padding-top:10px;position:relative;z-index:1}#onetrust-pc-sdk .ot-acc-cntr .ot-addtl-venbox{display:none}#onetrust-pc-sdk .ot-vensec-title{font-size:.813em;vertical-align:middle;display:inline-block}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;background:none;right:15px;top:15px;width:auto;position:absolute;font-weight:normal}#onetrust-pc-sdk .ot-cat-header{float:left;font-weight:600;font-size:.875em;line-height:1.5;max-width:90%;vertical-align:middle}#onetrust-pc-sdk .ot-vnd-item>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-vnd-item>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:2px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;width:calc(100% - 2px);float:left}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc{padding-left:20px;padding-right:20px;width:calc(100% - 40px);font-size:.812em;margin-bottom:10px;margin-top:15px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul{padding-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul li{padding-top:0;line-height:1.5;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout div+.ot-acc-grpdesc{margin-top:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:first-child{margin-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:last-child,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr:last-child{margin-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:20px;width:calc(100% - 40px);display:inline-block}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr{padding-left:20px;padding-right:15px;padding-bottom:0;width:calc(100% - 35px)}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp{padding-right:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%);right:20px;margin-top:-2px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr .ot-arw{width:15px;height:20px;margin-left:5px;color:dimgray}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{position:absolute;top:50%;transform:translateY(-50%);right:20px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:95px}#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler,#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler+a{margin-top:5px}#onetrust-pc-sdk #ot-lst-cnt{margin-top:1rem;max-height:calc(100% - 96px)}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list,#onetrust-pc-sdk .ot-vnd-serv{width:auto;padding:1rem 1.25rem;padding-bottom:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:600;font-size:.95em;line-height:2;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item{border:none;margin:0;padding:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button{outline:none;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button[aria-expanded=true],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button[aria-expanded=true]{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:first-child{margin-top:.25rem;border-top:unset}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child{margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child button{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 1.75rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-lbl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-cnt,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv{margin-bottom:1rem;padding:1rem .95rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr{padding:.5rem 0;margin:0;display:flex;width:100%;align-items:center;justify-content:space-between}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:first-child{margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:last-child{margin-right:.5rem;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-always-active{position:relative;right:unset;top:unset;transform:unset}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-plus-minus{top:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-arw-cntr{float:none;top:unset;right:unset;transform:unset;margin-top:-2px;position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-cat-header{flex:1;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-tgl{position:relative;transform:none;right:0;top:0;float:none}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox{position:relative;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label{padding:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label::before{position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox input{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0;z-index:1}#onetrust-pc-sdk .ot-vs-list{display:flex;flex-direction:column;padding:0;margin:.5rem 4px}#onetrust-pc-sdk .ot-vs-selc-all{display:flex;padding:0;float:unset;align-items:center;justify-content:flex-start}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf{justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:48px}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin:0;padding:0;margin-right:14px;justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-chkbox,#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-tgl{display:inline-block;right:unset;width:auto;height:auto;float:none}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:45px;height:25px}#onetrust-pc-sdk .ot-vs-selc-all .ot-sel-all-chkbox{margin-right:11px;margin-left:.75rem;display:flex;align-items:center}#onetrust-pc-sdk .ot-vs-selc-all .sel-all-hdr{margin:0 1.25rem;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-vnd-list-cnt #ot-selall-vencntr.ot-chkbox{float:unset;right:0}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:.5rem}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin-right:15px}#onetrust-pc-sdk #ot-sel-blk .ot-chkbox{right:unset}#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl{padding:0}#onetrust-pc-sdk .ot-vs-list{margin-top:.5rem}@media only screen and (max-width: 600px){#onetrust-pc-sdk{max-width:100%;min-width:100%}#onetrust-pc-sdk .ot-ftr-stacked button{width:100%}#onetrust-pc-sdk #ot-lst-cnt,#onetrust-pc-sdk #ot-pc-hdr{margin-top:0;padding:0 5px 0 10px;width:calc(100% - 25px)}}@media only screen and (max-width: 425px){#onetrust-pc-sdk.otPcPanel{left:0;min-width:100%;height:100%;top:0;border-radius:0}#onetrust-pc-sdk #ot-host-lst .ot-chkbox{margin-left:0}#onetrust-pc-sdk #ot-pc-content{margin:0 10px 0 20px}#onetrust-pc-sdk p{font-size:.7em}#onetrust-pc-sdk .ot-tgl-cntr{width:auto}#onetrust-pc-sdk #vendor-search-handler{font-size:1em}#onetrust-pc-sdk #ot-lst-cnt{height:calc(100% - 95px)}#onetrust-pc-sdk .ot-switch+p{max-width:80%}#onetrust-pc-sdk button{letter-spacing:.01em}#onetrust-pc-sdk .save-preference-btn-handler{margin-top:0}#onetrust-pc-sdk .ot-search-cntr{width:75%}}@media only screen and (max-width: 320px){#onetrust-pc-sdk #ot-fltr-cnt{margin-left:15px}}@media only screen and (max-width: 896px)and (max-height: 425px)and (orientation: landscape){#onetrust-pc-sdk{left:0;top:0;min-width:100%;height:100%;border-radius:0}#onetrust-pc-sdk button{letter-spacing:.02em}#onetrust-pc-sdk #ot-anchor{left:initial;right:50px}#onetrust-pc-sdk #ot-lst-title{margin-top:12px}#onetrust-pc-sdk #ot-lst-title *{font-size:inherit}#onetrust-pc-sdk #ot-pc-hdr input{margin-right:0;padding-right:45px}#onetrust-pc-sdk .ot-switch+p{max-width:85%}#onetrust-pc-sdk #ot-lst-cnt{max-height:none;overflow:initial}#onetrust-pc-sdk #ot-lst-cnt.no-results{height:auto}#onetrust-pc-sdk input{font-size:1em !important}#onetrust-pc-sdk p{font-size:.6em}#onetrust-pc-sdk #ot-pc-lst{overflow:auto}#onetrust-pc-sdk #ot-fltr-modal{width:100%;height:100%;max-height:none;top:0}#onetrust-pc-sdk #ot-sel-blk{position:static}#onetrust-pc-sdk #ot-fltr-cnt{height:250px;width:100%}#onetrust-pc-sdk.ot-shw-fltr #ot-anchor{display:none !important}#onetrust-pc-sdk.ot-shw-fltr #ot-pc-lst{height:100% !important;overflow:hidden;top:0px}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-cnt{margin:0;height:100%;padding:10px;top:0;width:calc(100% - 20px);position:absolute;right:0;left:0;max-width:none}#onetrust-pc-sdk.ot-shw-fltr .ot-fltr-scrlcnt{max-height:calc(100% - 65px)}}
            #onetrust-consent-sdk #onetrust-pc-sdk,
                #onetrust-consent-sdk #ot-search-cntr,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch.ot-toggle,
                #onetrust-consent-sdk #onetrust-pc-sdk ot-grp-hdr1 .checkbox,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title:after
                ,#onetrust-consent-sdk #onetrust-pc-sdk #ot-sel-blk,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-cnt,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-anchor {
                    background-color: #FFFFFF;
                }
               
            #onetrust-consent-sdk #onetrust-pc-sdk h3,
                #onetrust-consent-sdk #onetrust-pc-sdk h4,
                #onetrust-consent-sdk #onetrust-pc-sdk h5,
                #onetrust-consent-sdk #onetrust-pc-sdk h6,
                #onetrust-consent-sdk #onetrust-pc-sdk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-ven-lst .ot-ven-opts p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-li-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-sel-all-hdr span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-modal #modal-header,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-checkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-sel-blk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-lst-title h3,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .back-btn-handler p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .ot-ven-name,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .consent-category,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-label-status,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-chkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler 
                {
                    color: #696969;
                }
             #onetrust-consent-sdk #onetrust-pc-sdk .privacy-notice-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler + a,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-host-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-name a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-acc-hdr .ot-host-expand,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-content #ot-pc-desc .ot-link-btn
                    {
                        color: #3860BE;
                    }
            #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler:hover { text-decoration: underline;}
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-subgrp-tgl .ot-switch.ot-toggle
             {
                background-color: #F8F8F8;
            }
             #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-ven-dets
                            {
                                background-color: #F8F8F8;
                            }
        #onetrust-consent-sdk #onetrust-pc-sdk 
            button:not(#clear-filters-handler):not(.ot-close-icon):not(#filter-btn-handler):not(.ot-remove-objection-handler):not(.ot-obj-leg-btn-handler):not([aria-expanded]):not(.ot-link-btn),
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-active-leg-btn {
                background-color: #EA232B;border-color: #EA232B;
                color: #FFFFFF;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {
                border-color: #EA232B;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-remove-objection-handler{
                background-color: transparent;
                border: 1px solid transparent;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn {
                background-color: #FFFFFF;
                color: #78808E; border-color: #78808E;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:focus + .ot-switch, .ot-switch .ot-switch-nob, .ot-switch .ot-switch-nob:before,
            #onetrust-pc-sdk .ot-checkbox input[type="checkbox"]:focus + label::before,
            #onetrust-pc-sdk .ot-chkbox input[type="checkbox"]:focus + label::before {
                outline-color: #000000;
                outline-width: 1px;
            }
            #onetrust-pc-sdk .ot-host-item > button:focus, #onetrust-pc-sdk .ot-ven-item > button:focus {
                border: 1px solid #000000;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk *:focus,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-vlst-cntr > a:focus {
               outline: 1px solid #000000;
            }.ot-sdk-cookie-policy{font-family:inherit;font-size:16px}.ot-sdk-cookie-policy.otRelFont{font-size:1rem}.ot-sdk-cookie-policy h3,.ot-sdk-cookie-policy h4,.ot-sdk-cookie-policy h6,.ot-sdk-cookie-policy p,.ot-sdk-cookie-policy li,.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy th,.ot-sdk-cookie-policy #cookie-policy-description,.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}.ot-sdk-cookie-policy h4{font-size:1.2em}.ot-sdk-cookie-policy h6{font-size:1em;margin-top:2em}.ot-sdk-cookie-policy th{min-width:75px}.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy a:hover{background:#fff}.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}.ot-sdk-cookie-policy .ot-mobile-border{display:none}.ot-sdk-cookie-policy section{margin-bottom:2em}.ot-sdk-cookie-policy table{border-collapse:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy{font-family:inherit;font-size:1rem}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup{margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group-desc,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-table-header,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td{font-size:.9em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td a{font-size:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group{font-size:1em;margin-bottom:.6em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-title{margin-bottom:1.2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy>section{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th{min-width:75px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a:hover{background:#fff}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-mobile-border{display:none}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy section{margin-bottom:2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li{list-style:disc;margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li h4{display:inline-block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{border-collapse:inherit;margin:auto;border:1px solid #d7d7d7;border-radius:5px;border-spacing:initial;width:100%;overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border-bottom:1px solid #d7d7d7;border-right:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr th:last-child,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr td:last-child{border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:25%}.ot-sdk-cookie-policy[dir=rtl]{text-align:left}#ot-sdk-cookie-policy h3{font-size:1.5em}@media only screen and (max-width: 530px){.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) table,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tbody,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) th,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{display:block}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead tr{position:absolute;top:-9999px;left:-9999px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{margin:0 0 1em 0}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd),.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd) a{background:#f6f6f4}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td{border:none;border-bottom:1px solid #eee;position:relative;padding-left:50%}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{position:absolute;height:100%;left:6px;width:40%;padding-right:10px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) .ot-mobile-border{display:inline-block;background-color:#e4e4e4;position:absolute;height:100%;top:0;left:45%;width:2px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{content:attr(data-label);font-weight:bold}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border:none;border-bottom:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{display:block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:auto}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{margin:0 0 1em 0}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{height:100%;width:40%;padding-right:10px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{content:attr(data-label);font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead tr{position:absolute;top:-9999px;left:-9999px;z-index:-9999}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:1px solid #d7d7d7;border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td:last-child{border-bottom:0px}}
                
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h5,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group {
                        color: #696969;
                    }
                    
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title {
                            color: #696969;
                        }
                    
            
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th {
                            background-color: #F8F8F8;
                        }
                    
            .ot-floating-button__front{background-image:url('https://cdn.cookielaw.org/logos/static/ot_persistent_cookie.png')}</style><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js" class="optanon-category-C0002 "></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=G-1KHGEKLF89&amp;l=dataLayer&amp;cx=c" class="optanon-category-C0002 "></script></head>

<body class="page-template-default page page-id-152 page-child parent-pageid-138 wp-embed-responsive">
        <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KVJG7B2"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <style>header{min-height:60vh;background-color:#f0efec;border-bottom-left-radius:40px;border-bottom-right-radius:40px;background-position:right;background-size:cover;background-repeat:no-repeat}@media (max-width:991px){header.homepage{min-height:240px;border-bottom-left-radius:0;border-bottom-right-radius:0}header:not(.homepage){min-height:auto;background:unset!important;background-color:#f0efec!important}}header .header,header .header *{color:#003a70}header .header * h1,header .header h1{overflow-wrap:normal}@media (max-width:325px){header .header * .smaller-font,header .header .smaller-font{font-size:1.6875rem}}header .body,header .body *{color:#003a70}header .nav-container{position:relative;z-index:2}header #logo-nav-container,header #top-nav-container{-webkit-transition:all .5s;transition:all .5s}header #logo-white{display:none}header nav a{text-decoration:none;position:relative;color:#003a70;font-family:Raleway,sans-serif}header nav a::after{content:"";height:2px;width:100%;position:absolute;top:1.25rem;left:0;opacity:0;background-color:#e97600;-webkit-transition:all .3s;transition:all .3s}header nav a:hover{text-decoration:none;color:#003a70}header nav a:hover::after{opacity:1}header nav .current-menu-ancestor>a::after,header nav .current-menu-item>a::after{opacity:1}header nav a[href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene"],header nav a[href="https://ir.beigene.com/news-events/press-releases/"],header nav a[href="https://www.beigenemedical.com/"]{padding-right:20px}header nav a[href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene"]::before,header nav a[href="https://ir.beigene.com/news-events/press-releases/"]::before,header nav a[href="https://www.beigenemedical.com/"]::before{content:"";background-image:url(/wp-content/themes/beigene20/assets/build/images/external-link-blue.png);background-size:14px 14px;width:.875rem;height:.875rem;position:absolute;top:2px;right:0}header.homepage{min-height:100vh;position:relative}@media (max-width:991px){header.homepage{min-height:240px;background-size:cover!important;background-position:right!important}}header.homepage .header,header.homepage .header *{color:#fff}@media (max-width:576px){header.homepage .header{max-width:13.125rem}}@media (min-width:576px){header.homepage .header{max-width:28.125rem}}@media (min-width:991px){header.homepage .header{max-width:unset}}header.homepage .body,header.homepage .body *{color:#fff}header.homepage #logo-white{display:block}header.homepage #logo-blue{display:none}header.homepage .homepage-cutout{position:absolute;bottom:0;right:0;z-index:1;height:100%;width:auto}header.homepage .homepage-animation{position:absolute;top:0;left:0;width:100%;height:100%;border-bottom-left-radius:32px;border-bottom-right-radius:32px;background:url(https://assets.codepen.io/223936/beigene-hp-bg.svg),radial-gradient(circle,#787c77 0,#6d706c 53%,#343633 100%);background-position-x:0;background-repeat:repeat;-webkit-animation-name:example;animation-name:example;-webkit-animation-duration:60s;animation-duration:60s;-webkit-animation-iteration-count:infinite;animation-iteration-count:infinite;-webkit-animation-timing-function:linear;animation-timing-function:linear}@media (max-width:991px){header.homepage .homepage-animation{-webkit-animation-duration:300s;animation-duration:300s;background-size:100% auto}}@-webkit-keyframes example{from{background-position-x:0}to{background-position-x:500%}}@keyframes example{from{background-position-x:0}to{background-position-x:500%}}header #location-nav>ul>li{position:relative;cursor:pointer;font-weight:600;color:#003a70;padding-right:20px;padding-left:30px;display:inline}header #location-nav>ul>li::before{content:url(/wp-content/themes/beigene20/assets/build/images/globe-blue.svg);position:absolute;left:0;top:0}header #location-nav>ul>li::after{content:url(/wp-content/themes/beigene20/assets/build/images/arrow-blue.svg);position:absolute;right:0;top:-4px;-webkit-transition:all .3s;transition:all .3s}header #location-nav>ul>li.rotate::after{-webkit-transform:rotate(-180deg);transform:rotate(-180deg);top:-1px}header #location-nav>ul>li ul{position:absolute;left:0;overflow:hidden;height:0;z-index:3;-webkit-transition:all .3s;transition:all .3s;background-color:#fff;border-bottom-left-radius:20px;border-bottom-right-radius:20px;width:160px}header #location-nav>ul>li ul li{padding:3px 20px;color:#003a70!important;font-family:Raleway,sans-serif;font-weight:800;font-size:1rem;line-height:1.5rem}header #location-nav>ul>li ul li:first-child{padding-top:10px}header #location-nav>ul>li ul li:last-child{padding-bottom:10px}header #location-nav>ul>li ul li a{color:#003a70;font-size:1rem}header #utility-nav .utility-nav>li{margin-right:1.5625rem;font-weight:800;font-size:1rem}@media (max-width:1292px){header #utility-nav .utility-nav>li{font-size:.875rem;margin-right:.625rem}}header #utility-nav .utility-nav .menu-item-has-children{position:relative}header #utility-nav .utility-nav .menu-item-has-children .sub-menu{height:0;overflow:hidden;opacity:0;width:200px;position:absolute;top:100%;left:0;-webkit-transition:all .3s;transition:all .3s;list-style-type:none;padding-left:0}header #utility-nav .utility-nav .menu-item-has-children .sub-menu li{margin-top:-200px;-webkit-transition:all .3s;transition:all .3s;padding-top:10px}header #utility-nav .utility-nav .menu-item-has-children:hover .sub-menu li{margin-top:0}header #utility-nav-search input{border-radius:10px;border:1px solid #c4bfb6;font-size:15px;font-weight:600;color:#000;padding:10px 20px}@media (max-width:1199px){header #utility-nav-search input{width:150px}}header #utility-nav-search input::-webkit-input-placeholder{color:#c4bfb6}header #utility-nav-search input::-moz-placeholder{color:#c4bfb6}header #utility-nav-search input:-ms-input-placeholder{color:#c4bfb6}header #utility-nav-search input::-ms-input-placeholder{color:#c4bfb6}header #utility-nav-search input::placeholder{color:#c4bfb6}header #sticky-logo{-webkit-transition:all .5s;transition:all .5s;overflow:hidden;width:0;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-ms-flexbox;display:flex}header #sticky-logo img{height:45px;width:170px;min-width:170px;display:block}header #main-nav .main-nav>li a{font-size:1.875rem;font-weight:900;margin-right:1.875rem}@media (max-width:1340px){header #main-nav .main-nav>li a{font-size:1.375rem}}@media (max-width:1100px){header #main-nav .main-nav>li a{font-size:1.25rem}}header #main-nav .main-nav>li a::after{height:4px;top:2.5rem}header #main-nav.stickyNavOn .main-nav>li{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;min-width:-webkit-fit-content;min-width:-moz-fit-content;min-width:fit-content}header #main-nav.stickyNavOn .main-nav>li a{font-size:1.25rem;margin-right:1.25rem}@media (max-width:1199px){header #main-nav.stickyNavOn .main-nav>li a{font-size:1.125rem}header #main-nav.stickyNavOn .main-nav>li a:after{top:1.875rem}}@media (max-width:1060px){header #main-nav.stickyNavOn .main-nav>li a{font-size:.9375rem;margin-right:.9375rem}header #main-nav.stickyNavOn .main-nav>li a:after{top:1.875rem}}header #main-nav.stickyNavOn .main-nav>li .sub-menu li a{font-size:1.125rem}header #main-nav.stickyNavOn .main-nav>li .sub-menu li a:after{top:1.875rem}@media (max-width:1060px){header #main-nav.stickyNavOn .main-nav>li .sub-menu li a{font-size:.9375rem}}header #main-nav .menu-item-has-children{position:relative}header #main-nav .menu-item-has-children .sub-menu{position:absolute;top:100%;left:0;height:0;overflow:hidden;opacity:0;-webkit-transition:all 1s;transition:all 1s;min-width:400px;padding-left:0}header #main-nav .menu-item-has-children .sub-menu li{margin-top:-300px;-webkit-transition:all .5s;transition:all .5s;list-style-type:none;padding-top:1.875rem;-webkit-box-sizing:border-box;box-sizing:border-box}header #main-nav .menu-item-has-children .sub-menu li::after{top:100%}header #main-nav .menu-item-has-children .sub-menu li a{margin-right:0;font-size:1.5rem;font-weight:600}@media (max-width:1340px){header #main-nav .menu-item-has-children .sub-menu li a{font-size:1.25rem}header #main-nav .menu-item-has-children .sub-menu li a:after{top:1.5625rem}}@media (max-width:1100px){header #main-nav .menu-item-has-children .sub-menu li a{font-size:1.125rem}header #main-nav .menu-item-has-children .sub-menu li a:after{top:1.5625rem}}header #main-nav .menu-item-has-children .sub-menu li:last-child{padding-bottom:1.25rem}header #main-nav .menu-item-has-children:hover .sub-menu{opacity:1;-webkit-transition:all .5s;transition:all .5s}header #main-nav .menu-item-has-children:hover .sub-menu li{margin-top:0;-webkit-transition:all .5s;transition:all .5s}header.nav-white nav a{color:#fff}header.nav-white nav a:hover{color:#fff}header.nav-white nav a[href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene"],header.nav-white nav a[href="https://ir.beigene.com/news-events/press-releases/"],header.nav-white nav a[href="https://www.beigenemedical.com/"]{padding-right:20px}header.nav-white nav a[href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene"]::before,header.nav-white nav a[href="https://ir.beigene.com/news-events/press-releases/"]::before,header.nav-white nav a[href="https://www.beigenemedical.com/"]::before{content:"";background-image:url(/wp-content/themes/beigene20/assets/build/images/external-link-white.png)}header.nav-white #location-nav ul li,header.nav-white #top-nav-container ul li{color:#fff}header.nav-white #location-nav>ul>li{position:relative;cursor:pointer;font-weight:600;color:#fff;padding-right:20px;padding-left:30px;display:inline}header.nav-white #location-nav>ul>li::before{content:url(/wp-content/themes/beigene20/assets/build/images/globe.svg);position:absolute;left:0;top:0}header.nav-white #location-nav>ul>li::after{content:url(/wp-content/themes/beigene20/assets/build/images/arrow.svg);position:absolute;right:0;top:-4px;-webkit-transition:all .3s;transition:all .3s}header #menu-underlay{background-color:rgba(0,58,112,.9);border-bottom-left-radius:40px;border-bottom-right-radius:40px;position:absolute;top:0;left:0;width:100%;height:0;z-index:1;-webkit-transition:all .5s;transition:all .5s}header #mobile-nav-container{position:relative}header #mobile-nav-container ul{list-style-type:none;padding-left:0}header #mobile-nav-container #mobile-menu-burger{z-index:3;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center}header #mobile-nav-container #mobile-menu-burger .menu-open-icon{width:20px}header #mobile-nav-container #mobile-menu-burger .menu-close-icon{display:none}header #mobile-nav-container #mobile-nav-logo{z-index:3}header #mobile-nav-container #mobile-search-icon{z-index:1}header #mobile-nav-container #mobile-location-nav{z-index:1}header #mobile-nav-container #mobile-location-nav>ul>li{position:relative;padding-right:17px}header #mobile-nav-container #mobile-location-nav>ul>li::after{content:url(/wp-content/themes/beigene20/assets/build/images/arrow.svg);position:absolute;right:0;top:-30%;-webkit-transition:all .3s;transition:all .3s}header #mobile-nav-container #mobile-location-nav>ul>li.gray::after{content:url(/wp-content/themes/beigene20/assets/build/images/arrow-gray.svg)}header #mobile-nav-container #mobile-location-nav>ul>li>ul{height:0;overflow:hidden;position:absolute;top:calc(100% + 10px);right:0;-webkit-transition:all .3s;transition:all .3s;padding:0 15px;background:#fff;border-bottom-left-radius:15px;border-bottom-right-radius:15px;width:165px}header #mobile-nav-container #mobile-location-nav>ul>li>ul li{color:#003a70;font-family:Raleway,sans-serif}header #mobile-nav-container #mobile-location-nav>ul>li>ul li:first-child{padding-top:7px}header #mobile-nav-container #mobile-location-nav>ul>li>ul li:last-child{padding-bottom:7px}header #mobile-nav-container #mobile-location-nav>ul>li>ul li a{color:#003a70}header #mobile-nav-container #mobile-nav-slideout{overflow:hidden;height:0;-webkit-transition:all .3s;transition:all .3s;position:absolute;top:0;left:0;background-color:#003a70;z-index:2;padding-top:0}header #mobile-nav-container #mobile-nav-slideout>div{margin-top:60px;overflow:scroll}header #mobile-nav-container #mobile-nav-slideout>div hr{border-color:#fff;opacity:1;margin-top:.25rem}header #mobile-nav-container #mobile-nav-search input{border-radius:20px;border:1px solid #fff;background-color:#003a70;padding:9px 18px;font-size:.875rem;font-weight:500;color:#fff}header #mobile-nav-container #mobile-nav-search input::-webkit-input-placeholder{color:#fff}header #mobile-nav-container #mobile-nav-search input::-moz-placeholder{color:#fff}header #mobile-nav-container #mobile-nav-search input:-ms-input-placeholder{color:#fff}header #mobile-nav-container #mobile-nav-search input::-ms-input-placeholder{color:#fff}header #mobile-nav-container #mobile-nav-search input::placeholder{color:#fff}header #mobile-nav-container #mobile-main-nav>div{width:100%}header #mobile-nav-container #mobile-main-nav>div li{font-size:1.25rem;font-weight:800;margin-bottom:20px}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children{position:relative}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children::after{content:url(/wp-content/themes/beigene20/assets/build/images/arrow.svg);position:absolute;top:0;right:0;-webkit-transition:all .3s;transition:all .3s}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children.open::after{-webkit-transform:scaleY(-1);transform:scaleY(-1);top:6px}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children .sub-menu{height:0;overflow:hidden;-webkit-transition:all .3s;transition:all .3s;padding-left:15px}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children .sub-menu>li{margin-bottom:0;padding-top:10px}header #mobile-nav-container #mobile-main-nav>div .menu-item-has-children .sub-menu>li a{font-weight:500;font-size:18px}header #mobile-nav-container #mobile-main-nav.mobile-main-nav-not-homepage a{color:#fff!important}header #mobile-nav-container #mobile-utility-nav li{font-size:1rem;font-weight:700;margin-bottom:20px}header #mobile-nav-container #mobile-utility-nav .menu-item-has-children .sub-menu{height:0;overflow:hidden}header #mobile-nav-container #mobile-utility-nav.mobile-utility-nav-not-homepage a{color:#fff!important}header #mobile-nav-container #mobile-utility-nav a[href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene"]::before,header #mobile-nav-container #mobile-utility-nav a[href="https://ir.beigene.com/news-events/press-releases/"]::before,header #mobile-nav-container #mobile-utility-nav a[href="https://www.beigenemedical.com/"]::before{background-image:url(/wp-content/themes/beigene20/assets/build/images/external-link-white.png)}header .breadcrumbs a{color:#003a70;text-decoration:none;-webkit-transition:all .3s;transition:all .3s}header .breadcrumbs a:hover{color:#ed1c24}header .recruiting-dot{background-color:#04c900;border-radius:50%;width:14px;height:14px}@media (max-width:991px){header .clinical-trials-masthead-id p,header .clinical-trials-masthead-status p{margin-bottom:0}}@media (max-width:991px){header .clinical-trials-masthead-id p{padding-bottom:0}}@media (max-width:991px){header .clinical-trials-masthead-return-to-search,header .clinical-trials-masthead-return-to-search *{font-size:.875rem;font-weight:500}}@media (max-width:991px){header .clinical-trials-id-field a,header .clinical-trials-id-field p{font-size:1rem}}</style><header class="mb-2 mb-lg-5  pb-3 pb-lg-5" style="background: linear-gradient(
        90deg,
        rgba(240, 239, 236, 1) 0%,
        rgba(240, 239, 236, 1) 45%,
        rgba(240, 239, 236, 0.40) 65%,
        rgba(240, 239, 236, 0.40) 100%
    ) no-repeat center / 100% 100%, url('https://www.beigene.com/wp-content/uploads/2022/04/Pipeline.png') no-repeat right / auto 100%;">
        <!-- MOBILE NAV -->
    <div id="mobile-nav-container" class="d-block d-lg-none py-3">
        <div id="mobile-nav-sticky-container" class="w-100">
            <div id="mobile-menu-underlay"></div>
            <div class="container-fluid mobile-nav-container">
                <div id="mobile-logo-nav-container" class="row">
                    <!-- hamburger -->
                    <div id="mobile-menu-burger" class="col-3">
                        <img class="menu-open-icon" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/burger.svg" alt="Open menu">
                        <img class="menu-close-icon" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/close.svg" alt="Close menu">
                    </div>

                    <div id="mobile-nav-logo" class="col-6">
                        <a href="https://www.beigene.com">
                            <img class="white-logo d-none" width="160" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-white.svg" alt="logo">
                            <img class="blue-logo " width="160" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-blue.svg" alt="logo">
                        </a>
                    </div>

                    <div class="col-2 p-0 d-flex align-items-center justify-content-center">
                        <nav id="mobile-location-nav">
                            <ul class="list-no-style">
                                <li class="d-flex align-items-center gray"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/globe-gray.svg" alt="Language">
                                    <ul class="list-no-style d-flex flex-column justify-content-center">
                                        <li><a href="https://www.beigene.com.au/">Australia</a></li>
                                        <li>Canada <a href="https://www.beigene.ca/">EN</a>|<a href="https://www.beigene.ca/fr-ca">FR</a></li>
                                        <li><a href="https://www.beigene.com.cn/">China</a></li>
                                        <li><a href="https://www.beigene.de/">Germany</a></li>
                                        <li><a href="https://www.beigene.com/">Global</a></li>
                                        <li><a href="https://www.beigene.kr/">South Korea</a></li>
                                        <li><a href="https://www.beigene.es/">Spain</a></li>
                                        <li><a href="https://www.beigene.us/">US</a></li>
                                    </ul>
                                </li>
                            </ul>
                        </nav>
                    </div>

                    <div id="mobile-search-icon" class="col-1 p-0 d-flex align-items-center">
                        <img src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/search-gray.svg" alt=" Search">
                    </div>
                </div>
                <div class="row px-4">
                    <div id="mobile-nav-slideout" class="col-12 d-flex flex-column">
                        <div class="px-4">
                            <div id="mobile-nav-search" class="mb-4 mt-2">
                                <form role="search" method="get" action="https://www.beigene.com/">
    <input type="search" class="form-control" placeholder="Search" name="s" value="" title="Search">
</form>
                            </div>
                                                            <nav id="mobile-main-nav" class="w-100 d-flex align-items-center mobile-main-nav-not-homepage" aria-label="Top Menu">
                                    <div class="menu-main-container"><ul id="menu-main" class="mobile-main-nav list-no-style d-flex flex-column"><li id="menu-item-146" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-146"><a href="https://www.beigene.com/our-purpose/">Our Purpose</a>
<ul class="sub-menu">
	<li id="menu-item-147" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-147"><a href="https://www.beigene.com/our-purpose/innovating-sustainably/">Innovating Sustainably</a></li>
	<li id="menu-item-183" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-183"><a href="https://www.beigene.com/our-purpose/operating-responsibly/">Operating Responsibly</a></li>
	<li id="menu-item-182" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-182"><a href="https://www.beigene.com/our-purpose/equity-and-sustainability/">ESG Report &amp; Goals</a></li>
</ul>
</li>
<li id="menu-item-184" class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-184"><a href="https://www.beigene.com/our-science-and-medicines/">Our Science &amp; Medicines</a>
<ul class="sub-menu">
	<li id="menu-item-4444" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4444"><a href="https://www.beigene.com/our-science-and-medicines/research-and-development/">Our Research &amp; Development</a></li>
	<li id="menu-item-190" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-152 current_page_item menu-item-190"><a href="https://www.beigene.com/our-science-and-medicines/pipeline/" aria-current="page">Pipeline</a></li>
	<li id="menu-item-189" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-189"><a href="https://www.beigene.com/our-science-and-medicines/medicines/">Our Medicines</a></li>
	<li id="menu-item-3221" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3221"><a href="https://www.beigene.com/our-science-and-medicines/our-clinical-trials/">Our Clinical Trials</a></li>
	<li id="menu-item-185" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-185"><a href="https://www.beigene.com/our-science-and-medicines/becoming-an-investigator/">Becoming an Investigator</a></li>
	<li id="menu-item-187" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-187"><a href="https://www.beigene.com/our-science-and-medicines/manufacturing/">Manufacturing</a></li>
</ul>
</li>
<li id="menu-item-191" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-191"><a href="https://www.beigene.com/for-patients/">For Patients</a></li>
<li id="menu-item-193" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-193"><a href="https://www.beigene.com/our-company-and-people/">Our Company &amp; People</a>
<ul class="sub-menu">
	<li id="menu-item-197" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-197"><a href="https://www.beigene.com/our-company-and-people/mission-vision-values/">Our Mission, Vision &amp; Values</a></li>
	<li id="menu-item-196" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-196"><a href="https://www.beigene.com/our-company-and-people/our-history/">Our History</a></li>
	<li id="menu-item-195" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-195"><a href="https://www.beigene.com/our-company-and-people/leadership-and-board/">Leadership &amp; Board</a></li>
	<li id="menu-item-194" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-194"><a href="https://www.beigene.com/our-company-and-people/join-our-team/">Join Our Team</a></li>
	<li id="menu-item-4699" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4699"><a href="https://www.beigene.com/our-company-and-people/meet-beigene/">Meet BeiGene</a></li>
</ul>
</li>
</ul></div>                                </nav>
                                                        <hr>
                                                            <nav id="mobile-utility-nav" class="d-flex align-items-center mobile-utility-nav-not-homepage" aria-label="Top Menu">
                                    <div class="menu-utility-container"><ul id="menu-utility" class="mobile-utility-nav list-no-style d-flex flex-column"><li id="menu-item-4163" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-4163"><a href="http://ir.beigene.com/">Investors</a>
<ul class="sub-menu">
	<li id="menu-item-4159" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4159"><a href="http://ir.beigene.com/">NASDAQ Investors</a></li>
	<li id="menu-item-4161" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4161"><a href="http://hkexir.beigene.com/">HKEX Investors</a></li>
	<li id="menu-item-4162" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4162"><a href="https://sseir.beigene.com/en/">SSE Investors</a></li>
</ul>
</li>
<li id="menu-item-5432" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-5432"><a href="https://ir.beigene.com/news-events/press-releases/">News &amp; Media</a>
<ul class="sub-menu">
	<li id="menu-item-6163" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6163"><a href="https://www.beigene.com/corporate-press-kit/">Corporate Press Kit</a></li>
</ul>
</li>
<li id="menu-item-4154" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4154"><a href="https://www.beigene.com/partnering/">Partnering</a></li>
<li id="menu-item-5013" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5013"><a href="https://www.beigenemedical.com/">Medical Info</a></li>
<li id="menu-item-4153" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4153"><a href="https://www.beigene.com/suppliers/">Suppliers</a></li>
<li id="menu-item-5942" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5942"><a target="_blank" rel="noopener" href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene">Careers</a></li>
<li id="menu-item-4155" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4155"><a href="https://www.beigene.com/contact-us/">Contact Us</a></li>
</ul></div>                                </nav>
                                                    </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!-- DESKTOP NAV -->
    <div id="nav-container" class="d-none d-lg-block" style="height: 265.5px;">
        <div id="nav-sticky-container" class="w-100" style="z-index: 1000;">
            <div id="menu-underlay"></div>
            <div class="container-fluid pb-5 px-5 nav-container">
                <div id="top-nav-container" class="row pt-4">
                    <!-- location nav -->
                    <div class="col-2 d-flex align-items-center">
                        <nav id="location-nav">
                            <ul class="list-no-style">
                                <li>Global<ul class="list-no-style d-flex flex-column justify-content-center">
                                        <li><a href="https://www.beigene.com.au/">Australia</a></li>
                                        <li>Canada <a href="https://www.beigene.ca/">EN</a>|<a href="https://www.beigene.ca/fr-ca">FR</a></li>
                                        <li><a href="https://www.beigene.com.cn/">China</a></li>
                                        <li><a href="https://www.beigene.de/">Germany</a></li>
                                        <li><a href="https://www.beigene.com/">Global</a></li>
                                        <li><a href="https://www.beigene.kr/">South Korea</a></li>
                                        <li><a href="https://www.beigene.es/">Spain</a></li>
                                        <li><a href="https://www.beigene.us/">US</a></li>
                                    </ul>
                                </li>
                            </ul>
                        </nav>
                    </div>

                    <!-- utility nav -->
                    <div class="col-10 d-flex justify-content-end">
                                                    <nav id="utility-nav" class="d-flex align-items-center" aria-label="Top Menu">
                                <div class="menu-utility-container"><ul id="menu-utility-1" class="utility-nav list-no-style d-flex justify-content-end"><li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-4163"><a href="http://ir.beigene.com/">Investors</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4159"><a href="http://ir.beigene.com/">NASDAQ Investors</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4161"><a href="http://hkexir.beigene.com/">HKEX Investors</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4162"><a href="https://sseir.beigene.com/en/">SSE Investors</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-5432"><a href="https://ir.beigene.com/news-events/press-releases/">News &amp; Media</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6163"><a href="https://www.beigene.com/corporate-press-kit/">Corporate Press Kit</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4154"><a href="https://www.beigene.com/partnering/">Partnering</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5013"><a href="https://www.beigenemedical.com/">Medical Info</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4153"><a href="https://www.beigene.com/suppliers/">Suppliers</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5942"><a target="_blank" rel="noopener" href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4155"><a href="https://www.beigene.com/contact-us/">Contact Us</a></li>
</ul></div>                            </nav>
                            <div id="utility-nav-search">
								<form role="search" method="get" action="https://www.beigene.com/">
    <input type="search" class="form-control" placeholder="Search" name="s" value="" title="Search">
</form>
                            </div>
                                            </div>
                </div>
                <div id="logo-nav-container" class="row px-4 my-4">
                    <div class="col-12">
                        <a href="https://www.beigene.com">
                            <img id="logo-blue" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-blue.svg" alt="logo">
                            <img id="logo-white" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-white.svg" alt="logo">
                        </a>
                    </div>
                </div>
                <div class="row px-4">
                    <div class="col-12 d-flex">
                        <div id="sticky-logo">
                            <a href="https://www.beigene.com">
                                <img src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-white.svg" alt="logo">
                            </a>
                        </div>
                        <!-- Main Menu -->
                                                    <nav id="main-nav" class="d-flex align-items-center" aria-label="Top Menu">
                                <div class="menu-main-container"><ul id="menu-main-1" class="main-nav list-no-style d-flex justify-content-end"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-146"><a href="https://www.beigene.com/our-purpose/">Our Purpose</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-147"><a href="https://www.beigene.com/our-purpose/innovating-sustainably/">Innovating Sustainably</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-183"><a href="https://www.beigene.com/our-purpose/operating-responsibly/">Operating Responsibly</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-182"><a href="https://www.beigene.com/our-purpose/equity-and-sustainability/">ESG Report &amp; Goals</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-184"><a href="https://www.beigene.com/our-science-and-medicines/">Our Science &amp; Medicines</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4444"><a href="https://www.beigene.com/our-science-and-medicines/research-and-development/">Our Research &amp; Development</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-152 current_page_item menu-item-190"><a href="https://www.beigene.com/our-science-and-medicines/pipeline/" aria-current="page">Pipeline</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-189"><a href="https://www.beigene.com/our-science-and-medicines/medicines/">Our Medicines</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3221"><a href="https://www.beigene.com/our-science-and-medicines/our-clinical-trials/">Our Clinical Trials</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-185"><a href="https://www.beigene.com/our-science-and-medicines/becoming-an-investigator/">Becoming an Investigator</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-187"><a href="https://www.beigene.com/our-science-and-medicines/manufacturing/">Manufacturing</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-191"><a href="https://www.beigene.com/for-patients/">For Patients</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-193"><a href="https://www.beigene.com/our-company-and-people/">Our Company &amp; People</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-197"><a href="https://www.beigene.com/our-company-and-people/mission-vision-values/">Our Mission, Vision &amp; Values</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-196"><a href="https://www.beigene.com/our-company-and-people/our-history/">Our History</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-195"><a href="https://www.beigene.com/our-company-and-people/leadership-and-board/">Leadership &amp; Board</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-194"><a href="https://www.beigene.com/our-company-and-people/join-our-team/">Join Our Team</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4699"><a href="https://www.beigene.com/our-company-and-people/meet-beigene/">Meet BeiGene</a></li>
</ul>
</li>
</ul></div>                            </nav>
                                            </div>
                </div>
            </div>
        </div>
    </div>
    <div class="container-fluid px-3 px-lg-5 position-relative" style="z-index: 0;">
                <div class="row">
                                        									<div class="row">
                                        <div class="col">
                                            <p id="breadcrumbs" class="ps-4 breadcrumbs font-18"><span><span><a href="https://www.beigene.com/">Home</a> | <span><a href="https://www.beigene.com/our-science-and-medicines/">Our Science &amp; Medicines</a> | <span class="breadcrumb_last" aria-current="page">Pipeline</span></span></span></span></p>                                        </div>
                                    </div>
                                                <div class="col-9 col-lg-6">
                        <div class="ps-2 ps-lg-4">
                            <!-- Header text -->
                                                            <div class="header w-75 w-lg-100"><h1>Development Pipeline</h1>
</div>
                                                        
                            <!-- Body text -->
                                                            <div class="body  d-none d-lg-inline-block"><p>We are pursuing a broad and deep pipeline that with the potential to address 80 percent of the world’s cancers by cancer type. In addition to leveraging our internal research resources, we continually evaluate external pre-clinical and early-stage assets that might expand our pipeline and contribute to our durable competitive advantages.</p>
</div>
                            
                            <!-- CTA -->
                                                    </div>
                    </div>
                        </div>
    </div>
</header>
<main class="main">
    
	<div class="entry-content">
                
    <!-- Main block container -->
<div id="pipeline-container" class="container"><div id="tab"><a class="program-tab internal-tab active">Development Programs</a> <a class="program-tab collab-tab">Collaborations</a></div> <div class="pipeline-display"><div class="tab tab-internal"><div class="header-container"><div class="pdf-button-container"><a href="https://www.beigene.com/wp-content/uploads/2022/04/Pipeline_5.5.2022.pdf" target="_blank" class="cta-btn"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/download-pdf.svg" alt="download"> <span>Download PDF</span></a></div></div> <div class="pipeline-filters"><div class="filters-container"><form class="form-container"><span class="filter-fields"><span class="filter-by-text">Filter by:</span> <img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/filter-icon.svg" class="filter-icon"> <div class="filter-option"><div class="select"><select class="filter-molecules font-frieght"><option value="" disabled="disabled" selected="selected" class="label">Molecule/Asset</option> <option value="Azacitidine">Azacitidine</option><option value="BGB-10188">BGB-10188</option><option value="BGB-11417">BGB-11417</option><option value="BGB-15025">BGB-15025</option><option value="BGB-16673">BGB-16673</option><option value="BGB-3245">BGB-3245</option><option value="BGB-A445">BGB-A445</option><option value="Carfilzomib">Carfilzomib</option><option value="DKN-01">DKN-01</option><option value="Dexamethasone">Dexamethasone</option><option value="Fruquintinib">Fruquintinib</option><option value="Lenalidomide">Lenalidomide</option><option value="Lenvatinib">Lenvatinib</option><option value="Obinutuzumab">Obinutuzumab</option><option value="Ociperlimab">Ociperlimab</option><option value="Pamiparib">Pamiparib</option><option value="Posaconazole">Posaconazole</option><option value="Rituximab">Rituximab</option><option value="Sitravatinib">Sitravatinib</option><option value="Surufatinib">Surufatinib</option><option value="Surzebiclimab">Surzebiclimab</option><option value="Temozolomide">Temozolomide</option><option value="Tislelizumab">Tislelizumab</option><option value="Venetoclax">Venetoclax</option><option value="Zandelisib">Zandelisib</option><option value="Zanidatamab">Zanidatamab</option><option value="Zanubrutinib">Zanubrutinib</option></select></div></div> <div class="filter-option"><div class="select"><select class="font-frieght"><option value="" disabled="disabled" selected="selected" class="label">Indications</option> <option value="1L CLL/SLL">1L CLL/SLL</option><option value="1L ES-SCLC">1L ES-SCLC</option><option value="1L GC/GEJC">1L GC/GEJC</option><option value="1L HCC">1L HCC</option><option value="1L HCC ">1L HCC </option><option value="1L HER2+ BC and 1L HER2+ GC/GEJC">1L HER2+ BC and 1L HER2+ GC/GEJC</option><option value="1L HER2+ advanced/metastatic GC/EC">1L HER2+ advanced/metastatic GC/EC</option><option value="1L MCL">1L MCL</option><option value="1L MSI-H or dMMR CRC">1L MSI-H or dMMR CRC</option><option value="1L NSCLC">1L NSCLC</option><option value="1L PD-L1 high advanced NSCLC">1L PD-L1 high advanced NSCLC</option><option value="1L advanced ESCC">1L advanced ESCC</option><option value="1L advanced UBC">1L advanced UBC</option><option value="1L advanced nasopharyngeal cancer">1L advanced nasopharyngeal cancer</option><option value="1L maintenance platinum-sensitive GC">1L maintenance platinum-sensitive GC</option><option value="1L non-squamous NSCLC">1L non-squamous NSCLC</option><option value="1L squamous NSCLC">1L squamous NSCLC</option><option value="1L/2L GC/GEJ">1L/2L GC/GEJ</option><option value="2L + cervical cancer">2L + cervical cancer</option><option value="2L PD-L1+ advanced ESCC">2L PD-L1+ advanced ESCC</option><option value="2L advanced ESCC">2L advanced ESCC</option><option value="2L+ HER2+ BTC">2L+ HER2+ BTC</option><option value="2L/3L NSCLC">2L/3L NSCLC</option><option value="2L/3L maintenance platinum-sensitive OC">2L/3L maintenance platinum-sensitive OC</option><option value="Advanced GC/GEJC/HCC">Advanced GC/GEJC/HCC</option><option value="Advanced NSCLC after anti-PD-(L)1 therapy">Advanced NSCLC after anti-PD-(L)1 therapy</option><option value="Advanced OC and TNBC">Advanced OC and TNBC</option><option value="Advanced Solid Tumors ">Advanced Solid Tumors </option><option value="Advanced or metastatic, unresectable GC, CRC, NSCLC">Advanced or metastatic, unresectable GC, CRC, NSCLC</option><option value="Advanced solid tumors">Advanced solid tumors</option><option value="Advanced solid tumors with BRAF mutations">Advanced solid tumors with BRAF mutations</option><option value="Advanced triple negative BC">Advanced triple negative BC</option><option value="B-cell lymphoid malignancies">B-cell lymphoid malignancies</option><option value="B-cell malignancies">B-cell malignancies</option><option value="CD79B R/R DLBCL">CD79B R/R DLBCL</option><option value="CLL/SLL and B-cell NHL">CLL/SLL and B-cell NHL</option><option value="Localized ESCC">Localized ESCC</option><option value="Myeloid malignancies">Myeloid malignancies</option><option value="Previously treated B-cell malignancies">Previously treated B-cell malignancies</option><option value="Previously treated advanced MSI-high or dMMR solid tumors">Previously treated advanced MSI-high or dMMR solid tumors</option><option value="Previously treated unresectable HCC">Previously treated unresectable HCC</option><option value="Previously untreated LS-SCLC">Previously untreated LS-SCLC</option><option value="Previously untreated, stage III unresectable NSCLC">Previously untreated, stage III unresectable NSCLC</option><option value="R/R CLL/SLL">R/R CLL/SLL</option><option value="R/R DLBCL">R/R DLBCL</option><option value="R/R FL">R/R FL</option><option value="R/R MZL">R/R MZL</option><option value="R/R cHL">R/R cHL</option><option value="R/R multiple myeloma with t(11;14)">R/R multiple myeloma with t(11;14)</option><option value="Resectable ESCC">Resectable ESCC</option><option value="Resectable stage II or IIIA NSCLC">Resectable stage II or IIIA NSCLC</option></select></div></div> <div class="filter-option"><div class="select"><select class="filter-phases font-frieght"><option value="" disabled="disabled" selected="selected">Phase</option> <option value="Phase 1">Phase 1</option><option value="Phase 2">Phase 2</option><option value="Phase 3">Phase 3</option></select></div></div></span></form></div> <div class="search-field"><a href="" class="clear-filters-link">Clear filters</a> <div class="search-bar"><form class="desktop-search-form"><input type="text" placeholder="Search Our Pipeline" name="search" class="font-frieght"> <button type="submit" class="visually-hidden button"></button></form> <form class="mobile-search-form"><input type="text" placeholder="Search Our Pipeline" name="search" class="font-frieght"> <button type="submit" class="visually-hidden button"></button></form> <a href="" class="toggle-search-bar"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/white-magnifying-glass-icon.svg" class="filter-icon"></a></div></div></div> <div class="clear-filters-mobile"><a href="">Clear filters</a></div> <div class="pipeline-brick"><div class="pipeline"><div class="pipeline-labels"><div class="molecule-asset-container"><h5 class="font-frieght">Molecule/Asset</h5></div> <div class="indications-container"><h5 class="font-frieght">Indication(s)</h5></div> <div class="phase-container"><h5 class="font-frieght">Phase</h5></div></div> <!----> <div><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)</span> <!----></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="OciperlimabTislelizumabBAT1706antiVEGF3" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Ociperlimab + Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="OciperlimabTislelizumabChemotherapy5" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Obinutuzumab,Zanubrutinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib</span> <span class="drug-subheading"><span>+ <strong>Obinutuzumab</strong> (anti-CD20)					</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03332017" target="_blank">NCT03332017</a></span> <span>
                                                    BGB-3111-212
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R FL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zanubrutinib13" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="BGB-11417,Zanubrutinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-11417</span> <span class="drug-subheading"><span>monotherapy + zanubrutinib</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB1141727" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-24714 (SMAC Mimetic) +/- Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                    
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced Solid Tumors </h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB24714SMACMimeticChemotherapy29" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="BGB-11417,Azacitidine,Posaconazole"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-11417 + Azacitidine +/- Posaconazole</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04771130" target="_blank">NCT04771130</a></span> <span>
                                                    BGB-11417-103
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Myeloid malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB11417AzacitidinePosaconazole30" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03430843" target="_blank">NCT03430843</a></span> <span>
                                                    BGB-A317-302 (RATIONALE 302)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L advanced ESCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#Tislelizumab31" aria-expanded="false" aria-controls="Tislelizumab31" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="Tislelizumab31" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03412773" target="_blank">NCT03412773</a></span> <span>
                                                            BGB-A317-301 (RATIONALE 301)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HCC </h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03358875" target="_blank">NCT03358875</a></span> <span>
                                                            BGB-A317-303 (RATIONALE 303)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L/3L NSCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03419897" target="_blank">NCT03419897</a></span> <span>
                                                            BGB-A317-208 (RATIONALE 208)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Previously treated unresectable HCC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L MSI-H or dMMR CRC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03736889" target="_blank">NCT03736889</a></span> <span>
                                                            BGB-A317-209 (RATIONALE 209)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Previously treated advanced MSI-high or dMMR solid tumors</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Sitravatinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Sitravatinib</span> <span class="drug-subheading"><span>(multikinase inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04921358" target="_blank">NCT04921358</a></span> <span>
                                                    BGB-A317-Sitravatinib 301
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China, Australia</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced NSCLC after anti-PD-(L)1 therapy</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China, Australia</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabSitravatinib32" aria-expanded="false" aria-controls="TislelizumabSitravatinib32" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabSitravatinib32" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Sitravatinib</span> <span class="drug-subheading"><span>(multikinase inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03941873" target="_blank">NCT03941873</a></span> <span>
                                                            BGB-900-104
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced GC/GEJC/HCC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase1"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Sitravatinib</span> <span class="drug-subheading"><span>(multikinase inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03666143" target="_blank">NCT03666143</a></span> <span>
                                                            BGB-900-103
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, China</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="BGB-11417,Dexamethasone,Carfilzomib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span> BGB-11417 + Dexamethasone +/- Carfilzomib</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04973605" target="_blank">NCT04973605</a></span> <span>
                                                    BGB-11417-105
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R multiple myeloma with t(11;14)</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB11417DexamethasoneCarfilzomib33" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="BGB-16673"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-16673</span> <span class="drug-subheading"><span>(BTK-targeted CDAC)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT05006716" target="_blank">NCT05006716</a></span> <span>
                                                    BGB-16673-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#BGB1667334" aria-expanded="false" aria-controls="BGB1667334" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="BGB1667334" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div><div data-phase="phase1"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-16673</span> <span class="drug-subheading"><span>(BTK-targeted CDAC)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                            
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Surufatinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Surufatinib </span> <span class="drug-subheading"><span>(VEGFR, FGFR, CSF-1R inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04579757" target="_blank">NCT04579757</a></span> <span>
                                                    2020-012-GLOB1
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabSurufatinib35" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Zanubrutinib,Rituximab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib + Rituximab</span> <span class="drug-subheading"><span>(anti-CD20)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04002297" target="_blank">NCT04002297</a></span> <span>
                                                    BGB-3111-306
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L MCL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#ZanubrutinibRituximab36" aria-expanded="false" aria-controls="ZanubrutinibRituximab36" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="ZanubrutinibRituximab36" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib + Rituximab</span> <span class="drug-subheading"><span>(anti-CD20)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                            
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R MZL</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div></div></div></div><div data-molecule="Zanubrutinib,Venetoclax"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span> Zanubrutinib  +/- Venetoclax<sup>†</sup></span> <span class="drug-subheading"><span>(Bcl-2 inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03336333" target="_blank">NCT03336333</a></span> <span>
                                                    BGB-3111-304 (SEQUOIA)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L CLL/SLL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="ZanubrutinibVenetoclaxsupsup37" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div></div></div></div><div data-molecule="Pamiparib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Pamiparib</span> <span class="drug-subheading"><span>(PARP 1-2 inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03519230" target="_blank">NCT03519230</a></span> <span>
                                                    BGB-290-302
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L/3L maintenance platinum-sensitive OC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#Pamiparib38" aria-expanded="false" aria-controls="Pamiparib38" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="Pamiparib38" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Pamiparib</span> <span class="drug-subheading"><span>(PARP 1-2 inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03427814" target="_blank">NCT03427814</a></span> <span>
                                                            BGB-290-303 (PARALLEL 303)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L maintenance platinum-sensitive GC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Pamiparib</span> <span class="drug-subheading"><span>(PARP 1-2 inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03333915" target="_blank">NCT03333915</a></span> <span>
                                                            BGB-290-102
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced OC and TNBC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Zandelisib,Zanubrutinib,Rituximab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zandelisib</span> <span class="drug-subheading"><span><strong>Zanubrutinib</strong> or <strong>Rituximab*</strong></span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT02914938" target="_blank">NCT02914938</a></span> <span>
                                                    ME-401-002
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Switzerland, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">CLL/SLL and B-cell NHL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Switzerland, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zandelisib39" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Pamiparib,Temozolomide"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Pamiparib + Temozolomide</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03150810" target="_blank">NCT03150810</a></span> <span>
                                                    BGB-290-103
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="PamiparibTemozolomide40" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Zanubrutinib,Lenalidomide,Rituximab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib + Lenalidomide +/- Rituximab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04436107" target="_blank">NCT04436107</a></span> <span>
                                                    BGB-3111-110
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R DLBCL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="ZanubrutinibLenalidomideRituximab41" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <span class="drug-subheading"><span>(anti-PD-1)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04486391" target="_blank">NCT04486391</a></span> <span>
                                                    BGB-A317-314
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R cHL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#Tislelizumab42" aria-expanded="false" aria-controls="Tislelizumab42" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="Tislelizumab42" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab</span> <span class="drug-subheading"><span>(anti-PD-1)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04318080" target="_blank">NCT04318080</a></span> <span>
                                                            BGB-A317-210 (TIRHOL)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R cHL</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Ociperlimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Ociperlimab</span> <span class="drug-subheading"><span>(anti-TIGIT) +/- Tislelizumab
or Rituximab</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                    
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R DLBCL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Ociperlimab43" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab,Ociperlimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab</span> <span class="drug-subheading"><span>(anti-TIGIT)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04746924" target="_blank">NCT04746924</a></span> <span>
                                                    BGB-A317-A1217-302 (AdvanTIG-302)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L PD-L1 high advanced NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabOciperlimab44" aria-expanded="false" aria-controls="TislelizumabOciperlimab44" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabOciperlimab44" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab</span> <span class="drug-subheading"><span>(anti-TIGIT)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04732494" target="_blank">NCT04732494</a></span> <span>
                                                            BGB-A317-A1217-203 (AdvanTIG-203)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L PD-L1+ advanced ESCC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab</span> <span class="drug-subheading"><span>(anti-TIGIT)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04693234" target="_blank">NCT04693234</a></span> <span>
                                                            BGB-A317-A1217-202 (AdvanTIG-202)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L + cervical cancer</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div></div></div><div data-phase="phase1"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab</span> <span class="drug-subheading"><span>(anti-TIGIT)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04047862" target="_blank">NCT04047862</a></span> <span>
                                                            BGB-900-105
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Ociperlimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab  + Ociperlimab + BAT1706</span> <span class="drug-subheading"><span>(anti-VEGF)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04948697" target="_blank">NCT04948697</a></span> <span>
                                                    AdvanTIG-206
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabOciperlimabBAT170645" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab,Ociperlimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT05014815" target="_blank">NCT05014815</a></span> <span>
                                                    AdvanTIG-205
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabOciperlimabChemotherapy46" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab,Ociperlimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04866017" target="_blank">NCT04866017</a></span> <span>
                                                    BGB-A317-A1217-301 (AdvanTIG-301)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia,&nbsp;U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Previously untreated, stage III unresectable NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia,&nbsp;U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabOciperlimabConcurrentChemoradiotherapy47" aria-expanded="false" aria-controls="TislelizumabOciperlimabConcurrentChemoradiotherapy47" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabOciperlimabConcurrentChemoradiotherapy47" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04952597" target="_blank">NCT04952597</a></span> <span>
                                                            AdvanTIG-204
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Previously untreated LS-SCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Surzebiclimab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Surzebiclimab</span> <span class="drug-subheading"><span>(anti-TIM-3)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03744468" target="_blank">NCT03744468</a></span> <span>
                                                    BGB-900-102
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabSurzebiclimab48" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab,Fruquintinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Fruquintinib</span> <span class="drug-subheading"><span>(VEGFR inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04716634" target="_blank">NCT04716634</a></span> <span>
                                                    BGB-A317-fruquintinib-201
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced or metastatic, unresectable GC, CRC, NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabFruquintinib49" aria-expanded="false" aria-controls="TislelizumabFruquintinib49" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabFruquintinib49" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Fruquintinib</span> <span class="drug-subheading"><span>(VEGFR inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04577963" target="_blank">NCT04577963</a></span> <span>
                                                            2020-013-00US3
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in U.S</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced triple negative BC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in U.S</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="BGB-10188,Zanubrutinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-10188</span> <span class="drug-subheading"><span>(PI3K inhibitor) +/- <strong>Zanubrutinib</strong> (BTK inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04282018" target="_blank">NCT04282018</a></span> <span>
                                                    BGB-A317-3111-10188-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell lymphoid malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB1018850" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Zanubrutinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03734016" target="_blank">NCT03734016</a></span> <span>
                                                    BGB-3111-305 (ALPINE)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">R/R CLL/SLL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#Zanubrutinib51" aria-expanded="false" aria-controls="Zanubrutinib51" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="Zanubrutinib51" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                            
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">CD79B R/R DLBCL</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                            
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Previously treated B-cell malignancies</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanubrutinib</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/" target="_blank"></a></span> <span>
                                                            
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <!----></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <!----></div></div></div></div></div></div></div><div data-molecule="DKN-01,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + DKN-01</span> <span class="drug-subheading"><span>(anti-DKK1) + <strong>Chemotherapy</strong></span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04363801" target="_blank">NCT04363801</a></span> <span>
                                                    DEK-DKK1-P205 (DisTinGuish)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted&nbsp;in S. Korea, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L/2L GC/GEJ</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted&nbsp;in S. Korea, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabDKN0152" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="BGB-10188,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-10188</span> <span class="drug-subheading"><span>(PI3K inhibitor) +/- <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04282018" target="_blank">NCT04282018</a></span> <span>
                                                    BGB-A317-3111-10188-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB1018853" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="BGB-11417"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-11417</span> <span class="drug-subheading"><span>(Bcl-2 inhibitor) monotherapy</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04277637" target="_blank">NCT04277637</a></span> <span>
                                                    BGB-11417-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">B-cell malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB1141754" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab,Lenvatinib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Lenvatinib</span> <span class="drug-subheading"><span>(VEGFR kinase inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04401800" target="_blank">NCT04401800</a></span> <span>
                                                    BGB-A317-211
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabLenvatinib55" aria-expanded="false" aria-controls="TislelizumabLenvatinib55" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabLenvatinib55" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div><div data-phase="phase2"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Lenvatinib</span> <span class="drug-subheading"><span>(VEGFR kinase inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT05014828" target="_blank">NCT05014828</a></span> <span>
                                                            BGB-A317-212
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="BGB-3245"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-24714 +/- Chemotherapy</span> <span class="drug-subheading"><span>(SMAC Mimetic)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04249843" target="_blank">NCT04249843</a></span> <span>
                                                    BGB-3245-AU-001
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors with BRAF mutations</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB24714Chemotherapy56" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="BGB-3245"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-3245</span> <span class="drug-subheading"><span>(BRAF inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04249843" target="_blank">NCT04249843</a></span> <span>
                                                    BGB-3245-AU-001
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors with BRAF mutations</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB324557" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="BGB-3245"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-24714 (SMAC Mimetic) +/- Chemotherapy</span> <span class="drug-subheading"><span>(RAF inhibitor) + <strong>Mirdametinib</strong> (MEK inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03905148" target="_blank">NCT03905148</a></span> <span>
                                                    BGB-283/PD-0325901-AU-001
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB24714SMACMimeticChemotherapy58" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab,BGB-10188"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + BGB-10188</span> <span class="drug-subheading"><span>(PI3K inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04282018" target="_blank">NCT04282018</a></span> <span>
                                                    BGB-A317-3111-10188-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabBGB1018859" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Tislelizumab,BGB-15025"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + BGB-15025</span> <span class="drug-subheading"><span>(HPK1 inhibitor)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04649385" target="_blank">NCT04649385</a></span> <span>
                                                    BGB-A317-15025-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand, U.S.</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand, U.S.</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabBGB1502560" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab,BGB-A445"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + BGB-A445</span> <span class="drug-subheading"><span>(anti-OX40)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04215978" target="_blank">NCT04215978</a></span> <span>
                                                    BGB-A317-A445-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabBGBA44561" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemoradiotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03957590" target="_blank">NCT03957590</a></span> <span>
                                                    BGB-A317-311 (RATIONALE 311)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Localized ESCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabChemoradiotherapy62" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div></div></div></div><div data-molecule="Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03783442" target="_blank">NCT03783442</a></span> <span>
                                                    BGB-A317-306 (RATIONALE 306)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L advanced ESCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#TislelizumabChemotherapy63" aria-expanded="false" aria-controls="TislelizumabChemotherapy63" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="TislelizumabChemotherapy63" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03777657" target="_blank">NCT03777657</a></span> <span>
                                                            BGB-A317-305 (RATIONALE 305)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L GC/GEJC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04379635" target="_blank">NCT04379635</a></span> <span>
                                                            BGB-A317-315 (RATIONALE 315)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Resectable stage II or IIIA NSCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04379635" target="_blank">NCT04379635</a></span> <span>
                                                            BGB-A317-315 (RATIONALE 315)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L advanced nasopharyngeal cancer</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03924986" target="_blank">NCT03924986</a></span> <span>
                                                            BGB-A317-307 (RATIONALE 307)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L squamous NSCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03663205" target="_blank">NCT03663205</a></span> <span>
                                                            BGB-A317-304 (RATIONALE 304)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L non-squamous NSCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03967977" target="_blank">NCT03967977</a></span> <span>
                                                            BGB-A317-310 (RATIONALE 310)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L advanced UBC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04005716" target="_blank">NCT04005716</a></span> <span>
                                                            BGB-A317-312 (RATIONALE 312)
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L ES-SCLC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tislelizumab + Chemotherapy/ Chemoradiotherapy</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04974047" target="_blank">NCT04974047</a></span> <span>
                                                    BGB-A317-213
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Resectable ESCC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="TislelizumabChemotherapyChemoradiotherapy64" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Zanidatamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab</span> <span class="drug-subheading"><span>(anti-HER2 bi-specific antibody)</span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04466891" target="_blank">NCT04466891</a></span> <span>
                                                    ZWI-ZW25-203 (HERIZON-BTC-01)
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">2L+ HER2+ BTC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted Globally</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zanidatamab65" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Zanidatamab,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab + Chemotherapy+/- Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04276493" target="_blank">NCT04276493</a></span> <span>
                                                    BGB-A317-ZW25-101
                                                </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HER2+ BC and 1L HER2+ GC/GEJC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#ZanidatamabChemotherapyTislelizumab66" aria-expanded="false" aria-controls="ZanidatamabChemotherapyTislelizumab66" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="ZanidatamabChemotherapyTislelizumab66" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div><div data-phase="phase3"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab + Chemotherapy+/- Tislelizumab</span> <!----></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04276493" target="_blank">NCT04276493</a></span> <span>
                                                            BGB-A317-ZW25-101
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">1L HER2+ advanced/metastatic GC/EC</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in China, S. Korea</p>
</p></div></div></div></div></div></div></div></div> <div class="mb-2 font-frieght">* In collaboration with MEI Pharma<br>† This combination is being studied in the third cohort of NCT03336333.</div> <div class="font-frieght">1L/2L/3L: first/second/third line; BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene–positive; BTC, biliary tract cancer; CC, cervical cancer; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; DLBCL, diffuse large B-cell lymphoma; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; FL, follicular lymphoma; GBM, glioblastoma; gBRCA, germline breast cancer susceptibility gene; GC, gastric cancer; GEA, gastroesophageal adenocarcinoma; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2–, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; HPK1, hematopoietic progenitor kinase 1; LA NSCLC, locally-advanced non-small cell lung cancer; LS-SCLC, limited-stage small cell lung cancer; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; MSI, microsatellite instability; NHL, non-Hodgkin lymphoma; NPC, nasopharyngeal cancer; NSCLC, non–small cell lung cancer; OC, ovarian cancer; PD-L1: programmed death ligand-1; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; TNBC, triple-negative breast cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; UBC, urothelial bladder cancer; UC, urothelial carcinoma; VEGFR, vascular endothelial growth factor receptors; WM, Waldenström macroglobulinemia.</div></div></div></div><div class="tab tab-collaborative" style="display:none;"><div class="header-container"><div class="pdf-button-container"><a href="https://www.beigene.com/wp-content/uploads/2022/04/Pipeline_5.5.2022.pdf" target="_blank" class="cta-btn"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/download-pdf.svg" alt="download"> <span>Download PDF</span></a></div></div> <div class="pipeline-filters"><div class="filters-container"><form class="form-container"><span class="filter-fields"><span class="filter-by-text">Filter by:</span> <img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/filter-icon.svg" class="filter-icon"> <div class="filter-option"><div class="select"><select class="filter-molecules font-frieght"><option value="" disabled="disabled" selected="selected" class="label">Molecule/Asset</option> <option value="ABI-H3733">ABI-H3733</option><option value="AMG 176">AMG 176</option><option value="AMG 199^^">AMG 199^^</option><option value="AMG 256">AMG 256</option><option value="AMG 427^^">AMG 427^^</option><option value="AMG 506">AMG 506</option><option value="AMG 509^">AMG 509^</option><option value="AMG 650">AMG 650</option><option value="AMG 994">AMG 994</option><option value="Acapatamab">Acapatamab</option><option value="BGB-32451">BGB-32451</option><option value="DKN-01">DKN-01</option><option value="LBL-007">LBL-007</option><option value="Pavurutamab">Pavurutamab</option><option value="SEA-CD70">SEA-CD70</option><option value="Sitravatinib†">Sitravatinib†</option><option value="Sotorasib">Sotorasib</option><option value="Tarlatamab">Tarlatamab</option><option value="Tislelizumab">Tislelizumab</option><option value="Vebicorvir">Vebicorvir</option><option value="ZW49">ZW49</option><option value="Zanidatamab">Zanidatamab</option></select></div></div> <div class="filter-option"><div class="select"><select class="font-frieght"><option value="" disabled="disabled" selected="selected" class="label">Indications</option> <option value="AML">AML</option><option value="Advanced solid tumors">Advanced solid tumors</option><option value="BC, GC, GEA">BC, GC, GEA</option><option value="BTC">BTC</option><option value="Chronic Hepatitis B Virus">Chronic Hepatitis B Virus</option><option value="Chronic hepatitis B virus">Chronic hepatitis B virus</option><option value="GC/GEJC">GC/GEJC</option><option value="GEA">GEA</option><option value="HCC, GC/GEJC">HCC, GC/GEJC</option><option value="HER2 expressing cancers">HER2 expressing cancers</option><option value="Hematologic malignancies">Hematologic malignancies</option><option value="MDS, AML">MDS, AML</option><option value="MM">MM</option><option value="NSCLC, RCC, OC, MEL">NSCLC, RCC, OC, MEL</option><option value="Prostate cancer">Prostate cancer</option><option value="SCLC">SCLC</option><option value="Solid tumors">Solid tumors</option><option value="Solid tumors, CRC, NSCLC">Solid tumors, CRC, NSCLC</option></select></div></div> <div class="filter-option"><div class="select"><select class="filter-phases font-frieght"><option value="" disabled="disabled" selected="selected">Phase</option> <option value="Phase 1">Phase 1</option><option value="Phase 2">Phase 2</option><option value="Phase 3">Phase 3</option></select></div></div></span></form></div> <div class="search-field"><a href="" class="clear-filters-link">Clear filters</a> <div class="search-bar"><form class="desktop-search-form"><input type="text" placeholder="Search Our Pipeline" name="search" class="font-frieght"> <button type="submit" class="visually-hidden button"></button></form> <form class="mobile-search-form"><input type="text" placeholder="Search Our Pipeline" name="search" class="font-frieght"> <button type="submit" class="visually-hidden button"></button></form> <a href="" class="toggle-search-bar"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/white-magnifying-glass-icon.svg" class="filter-icon"></a></div></div></div> <div class="clear-filters-mobile"><a href="">Clear filters</a></div> <div class="pipeline-brick"><div class="pipeline"><div class="pipeline-labels"><div class="molecule-asset-container"><h5 class="font-frieght">Molecule/Asset</h5></div> <div class="indications-container"><h5 class="font-frieght">Indication(s)</h5></div> <div class="phase-container"><h5 class="font-frieght">Phase</h5></div></div> <!----> <div data-molecule="Tarlatamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Tarlatamab^^</span> <span class="drug-subheading"><span>(DLL3)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">SCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Tarlatamab1" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="AMG 256"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 256</span> <span class="drug-subheading"><span>(Anti-PD-1 x IL21 mutein)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG2562" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Sitravatinib†,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Sitravatinib<sup>†</sup></span> <span class="drug-subheading"><span>(multi-kinase inhibitor) + <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Mirati Therapeutics" src="https://www.beigenemedical.com/pipeline/partner_images/mirati.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">NSCLC, RCC, OC, MEL</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Mirati Therapeutics" src="https://www.beigenemedical.com/pipeline/partner_images/mirati.png"></span></div> <div class="indication-notes"><p><p>Commercial rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Sitravatinibsupsup4" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div></div></div></div><div data-molecule="Pavurutamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Pavurutamab^^</span> <span class="drug-subheading"><span> (BCMA)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">MM</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Pavurutamab6" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Sitravatinib†,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Sitravatinib<sup>†</sup></span> <span class="drug-subheading"><span>(monotherapy) + <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Mirati Therapeutics" src="https://www.beigenemedical.com/pipeline/partner_images/mirati.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">HCC, GC/GEJC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Mirati Therapeutics" src="https://www.beigenemedical.com/pipeline/partner_images/mirati.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><button type="button" data-bs-toggle="collapse" data-bs-target="#Sitravatinibsupsup7" aria-expanded="false" aria-controls="Sitravatinibsupsup7" class="collapse-button"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/arrow-blue.svg" class="collapse-arrow"></button></div></div></div> <div id="Sitravatinibsupsup7" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div><div data-phase="phase1"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Sitravatinib<sup>†</sup></span> <span class="drug-subheading"><span>(monotherapy) + <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><span><a href="https://clinicaltrials.gov/ct2/show/NCT04215978" target="_blank">NCT04215978</a></span> <span>
                                                            BGB-A317-A445-101
                                                        </span></div> <div class="drug-info d-none d-lg-block"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><!----> <div class="indication-notes"><p><p>Conducted in Australia, New Zealand</p>
</p></div></div></div></div></div></div></div></div><div data-molecule="Tislelizumab,Zanidatamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab<sup>††</sup></span> <span class="drug-subheading"><span>(HER2, bispecific antibody) + <strong>Chemotherapy</strong> + <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">GEA</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zanidatamabsupsup8" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div></div></div></div><div data-molecule="AMG 176"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 176</span> <span class="drug-subheading"><span>(Mcl-1, SM)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Hematologic malignancies</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG1769" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Zanidatamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab<sup>††</sup></span> <span class="drug-subheading"><span>(monotherapy)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">BTC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zanidatamabsupsup10" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="AMG 427^^"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 427^^</span> <span class="drug-subheading"><span>(FLT3)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">AML</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG42711" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Zanidatamab,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Zanidatamab<sup>††</sup> </span> <span class="drug-subheading"><span>+ <strong>Chemotherapy</strong> +/- <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">BC, GC, GEA</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Zanidatamabsupsup12" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="ZW49"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>ZW49</span> <span class="drug-subheading"><span>(HER2, bispecific ADC)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">HER2 expressing cancers</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Zymeworks" src="https://www.beigenemedical.com/pipeline/partner_images/zymeworks.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="ZW4914" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Acapatamab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Acapatamab^^</span> <span class="drug-subheading"><span>(PSMA)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Prostate cancer</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Acapatamab15" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="BGB-32451"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>BGB-3245<sup>1</sup></span> <span class="drug-subheading"><span>(BRAF)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Springworks			" src="https://www.beigenemedical.com/pipeline/partner_images/springworks.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Springworks			" src="https://www.beigenemedical.com/pipeline/partner_images/springworks.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="BGB3245sup1sup16" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="SEA-CD70"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>SEA-CD70</span> <span class="drug-subheading"><span>(anti-CD70)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Seagen" src="https://www.beigenemedical.com/pipeline/partner_images/seagen.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand&nbsp;</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">MDS, AML</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Seagen" src="https://www.beigenemedical.com/pipeline/partner_images/seagen.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in&nbsp;Asia ex-Japan, Australia, New Zealand&nbsp;</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="SEACD7017" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="AMG 509^"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 509^ </span> <span class="drug-subheading"><span>(STEAP1 XmAb)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Prostate cancer</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG50918" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="Tislelizumab,DKN-01"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>DKN-01</span> <span class="drug-subheading"><span>(DKK1) + <strong>Tislelizumab</strong> ± <strong>Chemotherapy</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Leap Theraputics" src="https://www.beigenemedical.com/pipeline/partner_images/leap.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">GC/GEJC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Leap Theraputics" src="https://www.beigenemedical.com/pipeline/partner_images/leap.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Asia ex-Japan, Australia, New Zealand</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="DKN0119" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="AMG 199^^"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 199^^</span> <span class="drug-subheading"><span>(MUC17)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">GC/GEJC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG19920" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="LBL-007,Tislelizumab"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>LBL-007</span> <span class="drug-subheading"><span>(LAG-3) + <strong>Tislelizumab</strong></span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Leads Biolabs" src="https://www.beigenemedical.com/pipeline/partner_images/leads.png" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Ex-China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Advanced solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Leads Biolabs" src="https://www.beigenemedical.com/pipeline/partner_images/leads.png"></span></div> <div class="indication-notes"><p><p>Commercial Rights in Ex-China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="LBL00721" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Vebicorvir"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Vebicorvir </span> <span class="drug-subheading"><span>(ABI-H0731) (HBV core inhibitor)*</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Assembly Bio" src="https://www.beigenemedical.com/pipeline/partner_images/assembly-bio.jpeg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Chronic hepatitis B virus</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Assembly Bio" src="https://www.beigenemedical.com/pipeline/partner_images/assembly-bio.jpeg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Vebicorvir22" class="collapse collapse-target-container"><div data-phase="phase2"><!----></div></div></div></div><div data-molecule="Sotorasib"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>Sotorasib</span> <span class="drug-subheading"><span>(KRAS G12C)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors, CRC, NSCLC</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg"></div> <div class="phase-bar phase-bar-2 complete"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="Sotorasib23" class="collapse collapse-target-container"><div data-phase="phase3"><!----></div></div></div></div><div data-molecule="AMG 650"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 650</span> <span class="drug-subheading"><span>(oral small molecule)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG65024" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="ABI-H3733"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>ABI-H3733</span> <span class="drug-subheading"><span>(HBV core inhibitor)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Assembly Bio" src="https://www.beigenemedical.com/pipeline/partner_images/assembly-bio.jpeg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Chronic Hepatitis B Virus</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Assembly Bio" src="https://www.beigenemedical.com/pipeline/partner_images/assembly-bio.jpeg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="ABIH373325" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="AMG 506"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 506</span> <span class="drug-subheading"><span>(FAP x 4-1BB, DARPin<sup>®</sup>)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG50626" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div><div data-molecule="AMG 994"><div class="drug-container"><div class="drug-indication-container"><div class="indication-content"><div class="molecule-asset-container content-section"><h5 class="font-frieght"><span>AMG 994</span> <span class="drug-subheading"><span>(bispecific antibody)</span></span></h5> <div class="indication-id-numbers"><!----> <!----></div> <div class="drug-info d-none d-lg-block"><div class="partner-info"><span class="font-frieght">Collaborator: </span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg" style="max-height: 60px; max-width: 150px;"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div></div> <div class="indications-container content-section"><h5 class="font-frieght">Solid tumors</h5></div> <div class="phases-container first-container"><div class="phases-content"><div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg"></div> <div class="phase-bar phase-bar-1"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg"></div> <div class="phase-bar phase-bar-2"></div> <div class="phase-container"><img src="https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg"></div></div></div> <div class="drug-info-mobile d-flex d-lg-none"><div class="partner-info"><span class="font-frieght">Partner</span> <span><img alt="Amgen" src="https://www.beigenemedical.com/pipeline/partner_images/amgen.svg"></span></div> <div class="indication-notes"><p><p>Commercial Rights in China</p>
</p></div></div> <div class="indication-collapse-button d-none d-lg-block"><!----></div></div></div> <div id="AMG99428" class="collapse collapse-target-container"><div data-phase="phase1"><!----></div></div></div></div> <div class="mb-2 font-frieght">^ BiTE, ^^ HLE BiTE, † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non Sq NSCLC, †† ZW25, * Assembly is conducting Phase 2 triple combination studies with VBR and a Phase 1 study of ABI-H3733, 1 By MapKure, a JV with SpringWorks.</div> <div class="font-frieght">CRC = colorectal cancer; NSCLC = non-small cell lung cancer; MM = multiple myeloma; AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; mCRPC = metastatic castration resistant prostate cancer; GC = gastric cancer; GEJC = gastroesophageal junction cancer; PC = pancreatic cancer; HCC = hepatocellular carcinoma; BC = breast cancer; GEA = gastroesophageal adenocarcinoma; BTC = biliary tract cancer; TNBC = triple-negative breast cancer; NET = neuroendocrine tumor; STS = soft-tissue sarcoma; iMCD = idiopathic multicentric castleman's disease; NB = neuroblastoma</div></div></div></div></div></div>
    <script>
    const setupPipelineDisplay = () => {
        var app = new Vue({
            el: '#pipeline-container',
            delimiters: ["[[", "]]"],
            data: {
                messages: "",
                phases: ['Phase 1','Phase 2', 'Phase 3'],
                loading: false,
                tabs: {
                    internal: {
                        name: 'internal',
                        molecules: [],
                        drugs: [],
                        indications: [],
                        filter: {
                            molecules: '',
                            indications: '',
                            drugs: '',
                            phases: '',
                            search: '',
                        },
                        abr: '1L/2L/3L: first/second/third line; BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene–positive; BTC, biliary tract cancer; CC, cervical cancer; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; DLBCL, diffuse large B-cell lymphoma; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; FL, follicular lymphoma; GBM, glioblastoma; gBRCA, germline breast cancer susceptibility gene; GC, gastric cancer; GEA, gastroesophageal adenocarcinoma; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2–, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; HPK1, hematopoietic progenitor kinase 1; LA NSCLC, locally-advanced non-small cell lung cancer; LS-SCLC, limited-stage small cell lung cancer; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; MSI, microsatellite instability; NHL, non-Hodgkin lymphoma; NPC, nasopharyngeal cancer; NSCLC, non–small cell lung cancer; OC, ovarian cancer; PD-L1: programmed death ligand-1; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; TNBC, triple-negative breast cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; UBC, urothelial bladder cancer; UC, urothelial carcinoma; VEGFR, vascular endothelial growth factor receptors; WM, Waldenström macroglobulinemia.', abr_sub: '* In collaboration with MEI Pharma<br/>† This combination is being studied in the third cohort of NCT03336333.',
                        no_results: false,
                    },

                    collaborative: {
                        name: 'collaborative',
                        molecules: [],
                        drugs: [],
                        indications: [],
                        filter: {
                            molecules: '',
                            indications: '',
                            drugs: '',
                            phases: '',
                            search: '',
                        },
                        abr: 'CRC = colorectal cancer; NSCLC = non-small cell lung cancer; MM = multiple myeloma; AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; mCRPC = metastatic castration resistant prostate cancer; GC = gastric cancer; GEJC = gastroesophageal junction cancer; PC = pancreatic cancer; HCC = hepatocellular carcinoma; BC = breast cancer; GEA = gastroesophageal adenocarcinoma; BTC = biliary tract cancer; TNBC = triple-negative breast cancer; NET = neuroendocrine tumor; STS = soft-tissue sarcoma; iMCD = idiopathic multicentric castleman\'s disease; NB = neuroblastoma',
                        abr_sub: '^ BiTE, ^^ HLE BiTE, † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non Sq NSCLC, †† ZW25, * Assembly is conducting Phase 2 triple combination studies with VBR and a Phase 1 study of ABI-H3733, 1 By MapKure, a JV with SpringWorks.',
                        no_results: false,
                    },
                },
                searchFormOpen: false
            },
            mounted() {
                this.retrievePipelineData();
            },
            methods: {
                getIndicationsToShow(tab) {
                    let showdrugs = [];
                    const drug = tab.drugs.slice();
                    drug.forEach(drug => {
                        if (drug.show == true) {
                            let showindications = [];
                            drug.indications.forEach((indication, index) => {
                                if (indication.show == true) {
                                    showindications.push(indication);
                                }
                            });
                            if (showindications.length > 0) {
                                let tempdrug = {...drug};
                                tempdrug.indications = showindications;
                                showdrugs.push(tempdrug);
                            }
                        }
                    });
                    return showdrugs;
                },
                clearFilteredResults(tab) {
                    tab.filter.molecules = '';
                    tab.filter.drugs = '';
                    tab.filter.phases = '';
                    tab.filter.indications = '';

                    tab.drugs.forEach(drug => {
                        drug.show = true;
                        tab.no_results = false;

                        drug.indications.forEach((indication, index) => {
                            indication.show = true;

                            if (index === 0) {
                                indication["display_name"] = true;
                            } else {
                                indication["display_name"] = false;
                            }
                        });
                    });
                },
                hideStyles(indication, tab) {
                    indication.show = false;
                    indication.display_name = false;
                    tab.no_results = false;
                },

                // hide/show drug name
                hideShow(objectName) {
                    for (var key of Object.keys(objectName)) {
                        objectName[key][0].display_name = true;
                    }
                },

                // hide/show drug name/molecule
                comparison(drugData, inputData, setValue) {
                    if (drugData.toLowerCase().includes(inputData.toLowerCase())) {
                        setValue = true;
                    }
                },

                // adding indication to object for search
                addIndication(objectName, drugName, indicationName) {
                    if (!objectName[drugName]) {
                        objectName[drugName] = [(indicationName)];
                    } else {
                        objectName[drugName].push(indicationName);
                    }

                    return objectName;
                },

                search(event, tab) {
                    event.preventDefault();

                    let searchDrugs = {};

                    let phaseTranslation = {
                        'Phase 1': 'phase1',
                        'Phase 2': 'phase2',
                        'Phase 3': 'phase3',
                    };

                    let searchInput = tab.filter.search;

                    if (tab.filter.search) {
                        tab.drugs.forEach(drug => {
                            drug.show = false;
                            drug.display_name = false;
                            tab.no_results = false;

                            this.comparison(drug.drugName, searchInput, drug.show)
                            if (drug.molecule) {
                                drug.molecule.forEach(molecule => {
                                    this.comparison(molecule, searchInput, drug.show)
                                });
                            }

                            drug.indications.forEach((indication) => {
                                indication.show = false;
                                indication.display_name = false;

                                if (indication.search.toLowerCase().includes(searchInput.toLowerCase())) {
                                    drug.show = true;
                                    indication.show = true;
                                    searchDrugs[drug.drugName];
                                    this.addIndication(searchDrugs, drug.drugName, indication);
                                }

                                for (var key of Object.keys(phaseTranslation)) {
                                    if (key.toLowerCase().includes(searchInput.toLowerCase())) {
                                        if (indication.search.toLowerCase().includes(phaseTranslation[key].toLowerCase())) {
                                            drug.show = true;
                                            indication.show = true;
                                            this.addIndication(searchDrugs, drug.drugName, indication);
                                        }
                                    }
                                }
                            });
                        });

                        this.hideShow(searchDrugs);
                    } else if (!tab.filter.search) {
                        tab.no_results = false;
                        this.clearFilteredResults(tab);
                        tab.no_results = false;
                    }

                    if (Object.keys(searchDrugs).length === 0 && tab.filter.search) {
                        tab.no_results = true;
                    }
                },

                evaluateFilters(tab) {
                    let phaseTranslation = {
                        'Phase 1': 'phase1',
                        'Phase 2': 'phase2',
                        'Phase 3': 'phase3',
                    };

                    let filteredDrugsIndication = {};

                    let showLength = 0;

                    tab.drugs.forEach(drug => {
                        if (tab.filter.molecules === '') {
                            drug.show = true;
                        } else {
                            drug.show = false;
                            tab.no_results = false;
                            if (drug.molecule) {
                                drug.molecule.forEach(mol => {
                                    if(mol.toLowerCase() === tab.filter.molecules.toLowerCase()) {
                                        drug.show = true;
                                    }
                                });
                            }
                        }

                        if (tab.filter.indications && tab.filter.phases) {
                            drug.indications.forEach((indication) => {
                                this.hideStyles(indication, tab);
                                if (indication.title.toLowerCase() === tab.filter.indications.toLowerCase() && indication.phase.toLowerCase() === phaseTranslation[tab.filter.phases]) {
                                    indication.show = true;
                                    drug.show = true;
                                    drug.display_name = true;
                                    filteredDrugsIndication[drug.drugName];
                                    this.addIndication(filteredDrugsIndication, drug.drugName, indication);
                                    this.hideShow(filteredDrugsIndication);
                                }
                            });
                        } else if (tab.filter.indications || tab.filter.phases) {
                            drug.indications.forEach((indication) => {
                                this.hideStyles(indication, tab);
                                if(indication.title.toLowerCase() === tab.filter.indications.toLowerCase() || indication.phase.toLowerCase() === phaseTranslation[tab.filter.phases]) {
                                    indication.show = true;
                                    drug.show = true;
                                    drug.display_name = true;
                                    filteredDrugsIndication[drug.drugName];
                                    this.addIndication(filteredDrugsIndication, drug.drugName, indication);
                                    this.hideShow(filteredDrugsIndication);
                                }
                            });
                        }

                        if (drug.show) {
                            drug.indications.forEach((indication) => {
                                if (indication.show) {
                                    showLength += 1;
                                }
                            });
                        }
                    });

                    // if there are no indications to show, show the no results text
                    if (showLength === 0) {
                        tab.no_results = true;
                    }
                },

                getPhaseImages(phaseName) {
                    var phaseMap = {
                        'phase1': {
                            'phase1': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg',
                            'phase2': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-incomplete.svg',
                            'phase3': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg',
                        },
                        'phase2': {
                            'phase1': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg',
                            'phase2': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg',
                            'phase3': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-incomplete.svg',
                        },
                        'phase3': {
                            'phase1': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg',
                            'phase2': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg',
                            'phase3': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg',
                        },
                        'filed': {
                            'phase1': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg',
                            'phase2': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg',
                            'phase3': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg',
                        },
                        'marketed': {
                            'phase1': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-1-complete.svg',
                            'phase2': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-2-complete.svg',
                            'phase3': 'https://www.beigene.com/wp-content/themes/beigene20/assets/images/pipeline/phase-3-complete.svg',
                        },
                    };

                    return phaseMap[phaseName];
                },

                retrievePipelineData() {
                    this.loading = true;

                    axios({
                        url: "/wp-json/hdmz/pipeline-ajax",
                        method: "get",
                        data: {}
                    })
                        .then((result) => {
                            this.loading = false;

                            const pipelineedges = result.data.data.getDrugListing.edges;
                            var counter = 0;
                            pipelineedges.forEach(node => {
                                counter++;
                                //lets establish which tab we are in
                                let current_tab = (node.node.fullpath.indexOf('Internal') != -1) ? this.tabs.internal : this.tabs.collaborative;

                                //create a show field for use when filtering
                                node.node.show = true;

                                // create a unique id for collapse functionality
                                node.node.elementId = (node.node.drugName.replace(/[^\w]/g,'')) + counter;

                                //populate molecules
                                if (node.node.molecule != null) {
                                    node.node.molecule.forEach(molecule => {
                                        if (current_tab.molecules.indexOf(molecule) === -1) {
                                            current_tab.molecules.push(molecule);
                                        }
                                    });
                                }

                                //populate the indications menu object with unique values
                                if (node.node.indications != null) {
                                    node.node.indications.forEach((indication, index) => {
                                        // create the search index
                                        let search_index = [];

                                        // assign a phase image map
                                        indication.phase_images = this.getPhaseImages(indication.phase);

                                        //show display name if the indication is first in drug
                                        if (index === 0) {
                                            indication["display_name"] = true;
                                        } else {
                                            indication["display_name"] = false;
                                        }

                                        if (current_tab.indications.indexOf(indication.title) === -1) {
                                            current_tab.indications.push(indication.title);
                                        }

                                        //as long as I have access to the indication set a show value
                                        indication.show = true;

                                        //grab subheading and push into search index
                                        if (node.node.subheading != null) {
                                            search_index.push([node.node.subheading]);
                                        } else {
                                            node.node.subheading = '';
                                        }

                                        // pushing all relevant indication values into search index
                                        for (var key of Object.keys(indication)) {
                                            //console.log(key);
                                            if (indication[key] && typeof indication[key] != "boolean") {
                                                if (key === "notes") {
                                                    let stripped_html = indication[key].replace(/<(.|\n)*?>/g, "");
                                                    stripped_html = stripped_html.replace(/(\r\n|\n|\r)/gm, " ");
                                                    search_index.push([stripped_html]);
                                                } else {
                                                    search_index.push([indication[key]]);
                                                }
                                            }
                                        }

                                        // pushing relevant drug information into search index
                                        search_index.push([node.node.drugName]);

                                        if (node.node.molecule) {
                                            node.node.molecule.forEach((molecule, index) => {
                                                search_index.push([molecule])
                                            });
                                        }

                                        // convert search index array into a string
                                        let search_index_string = search_index.join(" ");
                                        indication["search"] = search_index_string;
                                    });
                                } else {
                                    node.node.indications = [{'show':false}];
                                }
                                current_tab.drugs.push(node.node);
                            });

                            // current_tab is out of scope at this point
                            // so to make it easier we'll just re-sort each tab indications dropdown
                            // explicitly by name, rather than reference
                            this.tabs.internal.indications.sort();
                            this.tabs.collaborative.indications.sort();
                            this.tabs.internal.molecules.sort();
                            this.tabs.collaborative.molecules.sort();
                        })
                        .catch((err) => {
                            this.messages = "There was an error...";
                        });
                },

                toggleSearchForm: function() {
                    this.searchFormOpen = !this.searchFormOpen;
                },

                toggleTabs: function (tab) {
                    if (tab === "collaborative") {
                        // hide internal content
                        // show collab content
                        document.querySelector(".tab-collaborative").setAttribute("style", "display:block;");
                        document.querySelector(".tab-internal").setAttribute("style", "display:none;");

                        // set collab tab as active
                        document.querySelector(".internal-tab").classList.remove('active');
                        document.querySelector(".collab-tab").classList.add('active');
                    }

                    if (tab === "internal") {
                        // hide collab content
                        // show internal content
                        document.querySelector(".tab-collaborative").setAttribute("style", "display:none;");
                        document.querySelector(".tab-internal").setAttribute("style", "display:block;");

                        // set internal tab as active
                        document.querySelector(".collab-tab").classList.remove('active');
                        document.querySelector(".internal-tab").classList.add('active');
                    }
                },
            }
        })
    }

    document.addEventListener("DOMContentLoaded", function (event) {
        setupPipelineDisplay();
        document.querySelector(".tab-collaborative").setAttribute("style", "display:none;");
    });
</script>




<div class="wp-container-6 wp-block-columns are-vertically-aligned-center justify-content-center container">
<div class="wp-container-5 wp-block-column is-vertically-aligned-center justify-content-center px-3 align-self-center">
<div style="height:40px" aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="has-autumn-leaf-alt-color has-text-color">Pipeline Highlights</h2>



<p>For additional clinical trial information please visit <a href="http://clinicaltrials.gov/" target="_blank" rel="noreferrer noopener">clinicaltrials.gov</a>.</p>



<div class="wp-container-4 wp-block-columns pt-5 mb-0">
<div class="wp-container-1 wp-block-column">
<figure class="wp-block-video aligncenter"><video controls="" loop="" muted="" src="https://www.beigene.com/wp-content/uploads/2022/04/Tislelizumab_MOA_March 2022-compressed.mp4" playsinline="" id="html5_video_b8ieistbi3u"></video><figcaption><strong>Tislelizumab (BGB-A317</strong>), <br>an anti-PD-1 antibody</figcaption></figure>



<p class="has-text-align-center"></p>
</div>



<div class="wp-container-2 wp-block-column">
<figure class="wp-block-video aligncenter"><video controls="" loop="" muted="" src="https://www.beigene.com/wp-content/uploads/2022/04/Pamiparib_MOA_MRC Approved_March 2022-compressed.mp4" playsinline="" id="html5_video_ziakkerkkaa"></video><figcaption><strong>Pamiparib (BGB-290)</strong>, <br>a PARP1 and PARP2 inhibitor</figcaption></figure>



<p class="has-text-align-center"></p>
</div>



<div class="wp-container-3 wp-block-column mb-0">
<figure class="wp-block-video aligncenter"><video controls="" loop="" muted="" src="https://www.beigene.com/wp-content/uploads/2022/04/Ociperlimab MOA Video_MRC Approved March 2022-compressed.mp4" playsinline="" id="html5_video_kr03jgwfli"></video><figcaption><strong>Ociperlimab&nbsp;(BGB-A1217), </strong><br>a TIGIT inhibito</figcaption></figure>
</div>
</div>
</div>
</div>



                                                                                                                                           

    <div class="container py-3">
        <div class="row">
            <div class="col">
                <div class="simple-accordion-gray accordion accordion-flush" id="accordion-11">
                    <div class="accordion-item">
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-1">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-1" aria-expanded="false" aria-controls="accordion-11-body-1">
                                        Zanubrutinib (BGB-3111), a BTK inhibitor                                    </button>
                                </h2>

                                <div id="accordion-11-body-1" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-1" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Zanubrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-2">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-2" aria-expanded="false" aria-controls="accordion-11-body-2">
                                        Tislelizumab (BGB-A317), an anti-PD-1 antibody                                    </button>
                                </h2>

                                <div id="accordion-11-body-2" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-2" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Tislelizumab is a humanized monoclonal antibody against the immune checkpoint receptor PD-1 that is currently being evaluated in pivotal clinical trials globally and in China and for which we plan to commence additional pivotal trials as a monotherapy and in combination with standard of care to treat various solid and hematological cancers.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-3">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-3" aria-expanded="false" aria-controls="accordion-11-body-3">
                                        Pamiparib (BGB-290), a PARP1 and PARP2 inhibitor                                    </button>
                                </h2>

                                <div id="accordion-11-body-3" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-3" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Pamiparib is a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2 enzymes that is being evaluated as a potential monotherapy and in combinations for the treatment of various solid tumors. We believe that pamiparib has the potential to be differentiated from other PARP<br>
inhibitors because of its brain penetration, greater selectivity, strong DNA-trapping activity, and good oral bioavailability demonstrated in preclinical models.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-4">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-4" aria-expanded="false" aria-controls="accordion-11-body-4">
                                        Ociperlimab (BGB-A1217), an anti-TIGIT antibody                                    </button>
                                </h2>

                                <div id="accordion-11-body-4" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-4" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Ociperlimab is an investigational humanized IgG1-variant monoclonal antibody directed against TIGIT. An immune checkpoint molecule, ociperlimab is currently being investigated in two global Phase 3 clinical trials, the AdvanTIG-301 (NCT04866017) and AdvanTIG-302 (NCT04746924) trials, in combination with tislelizumab in NSCLC. To date, approximately 800 subjects have been enrolled across the ociperlimab development program, which includes six global trials in patients with lung cancers, esophageal squamous cell carcinoma, and cervical cancer.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-5">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-5" aria-expanded="false" aria-controls="accordion-11-body-5">
                                        BGB-11417, a small molecule Bcl-2 inhibitor                                    </button>
                                </h2>

                                <div id="accordion-11-body-5" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-5" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>BGB-11417 is an investigational small molecule Bcl-2 inhibitor. We have completed preclinical and investigational new drug (IND)-enabling studies of BGB-11417, which demonstrated potent activity and high selectivity against the pro-apoptotic protein Bcl-2. The molecule appears to be more potent than venetoclax and shows the potential to overcome resistance to venetoclax. Further, it is more selective than venetoclax for Bcl-2 relative to Bcl-xL. Finally, we believe that it is well-positioned to be combined with zanubrutinib.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-6">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-6" aria-expanded="false" aria-controls="accordion-11-body-6">
                                        BGB-A445, an OX40 agonist antibody                                    </button>
                                </h2>

                                <div id="accordion-11-body-6" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-6" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>BGB-A445 is an investigational agonistic antibody directed to the OX40 antigen. BGB-A445 is a non-ligand competing antibody that does not disrupt OX40 to OX40 ligand engagement. Preclinical experiments showed that BGB-A445 had increasing effectiveness at higher doses versus an antibody that was ligand-competing, which showed falling effectiveness at higher doses. BGB-A445 has also showed in preclinical tests the potential to be combined with several agents, such as tislelizumab, as well as a TLR9 agonist, a PI3Kδ inhibitor, sitravatinib, and chemotherapy.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-7">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-7" aria-expanded="false" aria-controls="accordion-11-body-7">
                                        Surzebiclimab (BGB-A425), an anti-TIM3 antibody                                    </button>
                                </h2>

                                <div id="accordion-11-body-7" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-7" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>BGB-A425 is an investigational humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). BGB-A425 is being evaluated in combination with tislelizumab.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-8">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-8" aria-expanded="false" aria-controls="accordion-11-body-8">
                                        BGB-15025, a small molecule HPK1 inhibitor                                    </button>
                                </h2>

                                <div id="accordion-11-body-8" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-8" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>BGB-15025 is an investigational small molecule inhibitor of HPK1, which is a key negative feedback regulator of TCR signaling. Inhibition of HPK1 leads to enhanced T-cell activation pre-clinically. In addition, preclinical studies showed that BGB-15025 exhibits combination activity with tislelizumab and has a wide therapeutic window.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-9">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-9" aria-expanded="false" aria-controls="accordion-11-body-9">
                                        Sitravatinib, a multi-kinase inhibitor                                    </button>
                                </h2>

                                <div id="accordion-11-body-9" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-9" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Sitravatinib is an investigational spectrum-selective kinase inhibitor, which potently inhibits receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER), and split family receptors (VEGFR2, KIT). In January 2018, we entered into an exclusive license agreement with Mirati Therapeutics, Inc. (Mirati) for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan and certain other countries), Australia and New Zealand.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-10">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-10" aria-expanded="false" aria-controls="accordion-11-body-10">
                                        Zanidatamab (ZW25), a bispecific HER2-targeted antibody                                    </button>
                                </h2>

                                <div id="accordion-11-body-10" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-10" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Zanidatamab, a novel investigational Azymetric™ bispecific antibody targeting HER2, is currently in late-stage clinical development with Zymeworks Inc. BeiGene has development and commercial rights to zanidatamab in Asia (excluding Japan), Australia, and New Zealand.</p>
                                    </div>
                                </div>
                                                                                    <h2 class="accordion-header fw-700" id="accordion-11-header-11">
                                    <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#accordion-11-body-11" aria-expanded="false" aria-controls="accordion-11-body-11">
                                        Lifirafenib (BGB-283) and BGB-3245, inhibitors of RAF                                    </button>
                                </h2>

                                <div id="accordion-11-body-11" class="accordion-collapse collapse" aria-labelledby="accordion-11-header-11" data-bs-parent="#accordion-11">
                                    <div class="accordion-body">
                                        <p>Lifirafenib is an investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities. We believe that lifirafenib as monotherapy or in combination with other agents may have potential for treating various malignancies such as melanoma, NSCLC, and endometrial cancer. Lifirafenib has shown antitumor activity in preclinical models and in cancer patients with tumors harboring BRAF V600E mutations, non-V600E BRAF mutations or KRAS/NRAS mutations. We have been developing lifirafenib for the treatment of cancers with aberrations in the mitogen-activated protein kinase (MAPK), pathway, including BRAF gene mutations and KRAS/NRAS gene mutations where first generation BRAF inhibitors are not effective.</p>
<p>BeiGene is working with SpringWorks Therapeutics, Inc. (SpringWorks) in a global clinical collaboration to evaluate the safety, tolerability, and preliminary efficacy of lifirafenib in combination with SpringWorks’ investigational MEK inhibitor, mirdametinib (PD-0325901), in patients with advanced solid tumors.</p>
<p>In addition to the collaboration, BeiGene and SpringWorks formed a separate company, MapKure, LLC, to develop BGB-3245, an investigational, selective next-generation RAF kinase inhibitor discovered by BeiGene scientists.</p>
                                    </div>
                                </div>
                                            </div>
                </div>
            </div>
        </div>
    </div>
 
        	</div><!-- .entry-content -->
</main>

<footer class="pt-4 pt-lg-5 pb-3 mt-5">
    <div class="container-fluid">
        <div class="row px-3 px-lg-5">
            <div class="col-12 col-lg-4 d-none d-lg-block">
                                    <nav id="" class="" aria-label="Top Menu">
                        <div class="menu-main-container"><ul id="menu-main-2" class="footer-main-menu list-no-style d-flex flex-column"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-146"><a href="https://www.beigene.com/our-purpose/">Our Purpose</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-184"><a href="https://www.beigene.com/our-science-and-medicines/">Our Science &amp; Medicines</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-191"><a href="https://www.beigene.com/for-patients/">For Patients</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-193"><a href="https://www.beigene.com/our-company-and-people/">Our Company &amp; People</a></li>
</ul></div>                    </nav>
                            </div>
            <div class="d-none d-lg-block col-lg-2">
                <!-- utility nav -->
                                    <nav id="" class="" aria-label="Top Menu">
                        <div class="menu-utility-container"><ul id="menu-utility-2" class="footer-utility-menu list-no-style d-flex flex-column"><li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-4163"><a href="http://ir.beigene.com/">Investors</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-5432"><a href="https://ir.beigene.com/news-events/press-releases/">News &amp; Media</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4154"><a href="https://www.beigene.com/partnering/">Partnering</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5013"><a href="https://www.beigenemedical.com/">Medical Info</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4153"><a href="https://www.beigene.com/suppliers/">Suppliers</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-5942"><a target="_blank" rel="noopener" href="https://beigene.wd5.myworkdayjobs.com/en-US/BeiGene">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4155"><a href="https://www.beigene.com/contact-us/">Contact Us</a></li>
</ul></div>                    </nav>
                            </div>
            <div class="col-12 col-lg-2 pt-3 pb-4 py-lg-0">
                <!-- footer nav -->
                                    <nav id="" class="" aria-label="Top Menu">
                        <div class="menu-footer-container"><ul id="menu-footer" class="footer-menu list-no-style d-flex flex-column"><li id="menu-item-5494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5494"><a href="https://www.beigene.com/privacy-policy/">Privacy</a></li>
<li id="menu-item-5383" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5383"><a href="https://www.beigene.com/our-science-and-medicines/expanded-access-programs/">Accessibility</a></li>
<li id="menu-item-4171" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4171"><a href="https://www.beigene.com/terms-conditions/">Terms of Use</a></li>
<li id="menu-item-5692" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5692"><a href="https://www.beigene.com/sitemap/">Sitemap</a></li>
</ul></div>                    </nav>
                            </div>
        </div>
        <div class="row px-3 px-lg-5 pt-5 footer-bottom-row">
            <div class="col-12 col-lg-6">
                <img class="footer-company-logo" src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/images/logo-white.svg" alt="Logo">
            </div>
            <div class="col-12 col-lg-6 mt-4 mt-lg-0 text-center text-lg-end">
                
	<aside class="widget-area" role="complementary" aria-label="Footer">
							<div class="widget-column footer-widget-1">
					<section id="block-7" class="widget widget_block">
<ul class="wp-container-7 is-content-justification-right wp-block-social-links has-icon-color is-style-logos-only"><li style="color: #ffffff; " class="wp-social-link wp-social-link-twitter wp-block-social-link"><a href="https://twitter.com/BeiGeneGlobal" rel="noopener nofollow" target="_blank" class="wp-block-social-link-anchor"><svg width="24" height="24" viewBox="0 0 24 24" version="1.1" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"><path d="M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z"></path></svg><span class="wp-block-social-link-label screen-reader-text">Twitter</span></a></li>

<li style="color: #ffffff; " class="wp-social-link wp-social-link-linkedin wp-block-social-link"><a href="https://www.linkedin.com/company/beigene" rel="noopener nofollow" target="_blank" class="wp-block-social-link-anchor"><svg width="24" height="24" viewBox="0 0 24 24" version="1.1" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"><path d="M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z"></path></svg><span class="wp-block-social-link-label screen-reader-text">LinkedIn</span></a></li>

<li style="color: #ffffff; " class="wp-social-link wp-social-link-youtube wp-block-social-link"><a href="https://www.youtube.com/channel/UCJPyN9QBGWtLvhHSqq5ne8Q" rel="noopener nofollow" target="_blank" class="wp-block-social-link-anchor"><svg width="24" height="24" viewBox="0 0 24 24" version="1.1" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false"><path d="M21.8,8.001c0,0-0.195-1.378-0.795-1.985c-0.76-0.797-1.613-0.801-2.004-0.847c-2.799-0.202-6.997-0.202-6.997-0.202 h-0.009c0,0-4.198,0-6.997,0.202C4.608,5.216,3.756,5.22,2.995,6.016C2.395,6.623,2.2,8.001,2.2,8.001S2,9.62,2,11.238v1.517 c0,1.618,0.2,3.237,0.2,3.237s0.195,1.378,0.795,1.985c0.761,0.797,1.76,0.771,2.205,0.855c1.6,0.153,6.8,0.201,6.8,0.201 s4.203-0.006,7.001-0.209c0.391-0.047,1.243-0.051,2.004-0.847c0.6-0.607,0.795-1.985,0.795-1.985s0.2-1.618,0.2-3.237v-1.517 C22,9.62,21.8,8.001,21.8,8.001z M9.935,14.594l-0.001-5.62l5.404,2.82L9.935,14.594z"></path></svg><span class="wp-block-social-link-label screen-reader-text">YouTube</span></a></li></ul>
</section>					</div>
					</aside><!-- .widget-area -->

                <p class="mb-0">© 2022 BeiGene, Inc.</p>
            </div>
        </div>
    </div>
</footer>
        <style>.wp-container-1 > .alignleft { float: left; margin-inline-start: 0; margin-inline-end: 2em; }.wp-container-1 > .alignright { float: right; margin-inline-start: 2em; margin-inline-end: 0; }.wp-container-1 > .aligncenter { margin-left: auto !important; margin-right: auto !important; }</style>
<style>.wp-container-2 > .alignleft { float: left; margin-inline-start: 0; margin-inline-end: 2em; }.wp-container-2 > .alignright { float: right; margin-inline-start: 2em; margin-inline-end: 0; }.wp-container-2 > .aligncenter { margin-left: auto !important; margin-right: auto !important; }</style>
<style>.wp-container-3 > .alignleft { float: left; margin-inline-start: 0; margin-inline-end: 2em; }.wp-container-3 > .alignright { float: right; margin-inline-start: 2em; margin-inline-end: 0; }.wp-container-3 > .aligncenter { margin-left: auto !important; margin-right: auto !important; }</style>
<style>.wp-container-4 {display: flex;gap: 2em;flex-wrap: nowrap;align-items: center;}.wp-container-4 > * { margin: 0; }</style>
<style>.wp-container-5 > .alignleft { float: left; margin-inline-start: 0; margin-inline-end: 2em; }.wp-container-5 > .alignright { float: right; margin-inline-start: 2em; margin-inline-end: 0; }.wp-container-5 > .aligncenter { margin-left: auto !important; margin-right: auto !important; }</style>
<style>.wp-container-6 {display: flex;gap: 2em;flex-wrap: nowrap;align-items: center;}.wp-container-6 > * { margin: 0; }</style>
<style>.wp-container-7 {display: flex;gap: 0.5em;flex-wrap: wrap;align-items: center;justify-content: flex-end;}.wp-container-7 > * { margin: 0; }</style>
<link rel="stylesheet" id="pipeline_block-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/blocks/pipeline.css?ver=1" type="text/css" media="all">
<link rel="stylesheet" id="simple-accordion-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/blocks/simple-accordion.css?ver=1" type="text/css" media="all">
<link rel="stylesheet" id="footer-css" href="https://www.beigene.com/wp-content/themes/beigene20/assets/build/css/footer.css?ver=1" type="text/css" media="all">
<script src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/libs/js/bootstrap.js?ver=5.1.3" id="hdmz-bootstrap-js"></script>
<script src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/js/main.js?ver=1" id="hdmz-main-js"></script>
<script src="https://www.beigene.com/wp-content/themes/beigene20/assets/build/js/masthead.js?ver=1" id="masthead-js"></script>
<script src="https://cdn.jsdelivr.net/npm/vue@2.6.14?ver=2.6.14" id="vuejs-js"></script>
<script src="https://cdn.jsdelivr.net/npm/axios/dist/axios.min.js?ver=0.26.0" id="axios-js"></script>
        <script type="text/javascript">
_linkedin_partner_id = "4271577";
window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || [];
window._linkedin_data_partner_ids.push(_linkedin_partner_id);
</script><script type="text/javascript">
(function(l) {
if (!l){window.lintrk = function(a,b){window.lintrk.q.push([a,b])};
window.lintrk.q=[]}
var s = document.getElementsByTagName("script")[0];
var b = document.createElement("script");
b.type = "text/javascript";b.async = true;
b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js";
s.parentNode.insertBefore(b, s);})(window.lintrk);
</script>
<noscript>
<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4271577&fmt=gif" />
</noscript>    

<img src="https://t.co/i/adsct?bci=3&amp;eci=2&amp;event_id=2a22a963-33bf-4b98-b4e4-293f0a1b255c&amp;events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&amp;p_id=Twitter&amp;p_user_id=0&amp;pl_id=1b8066cd-aec8-4e9c-9e9b-abc357232d47&amp;tw_document_href=https%3A%2F%2Fwww.beigene.com%2Four-science-and-medicines%2Fpipeline%2F&amp;tw_iframe_status=0&amp;tw_order_quantity=0&amp;tw_sale_amount=0&amp;txn_id=o83cw&amp;type=javascript&amp;version=2.3.26" height="1" width="1" style="display: none;"><img height="1" width="1" class="optanon-category-C0004 ot-vscat-C0004 " style="display: none;" src="https://analytics.twitter.com/i/adsct?bci=3&amp;eci=2&amp;event_id=2a22a963-33bf-4b98-b4e4-293f0a1b255c&amp;events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&amp;p_id=Twitter&amp;p_user_id=0&amp;pl_id=1b8066cd-aec8-4e9c-9e9b-abc357232d47&amp;tw_document_href=https%3A%2F%2Fwww.beigene.com%2Four-science-and-medicines%2Fpipeline%2F&amp;tw_iframe_status=0&amp;tw_order_quantity=0&amp;tw_sale_amount=0&amp;txn_id=o83cw&amp;type=javascript&amp;version=2.3.26"><script type="text/javascript" id="">(function(){function f(a){switch(a.type){case "timeupdate":b[a.target.id].current=Math.round(a.target.currentTime);var d=Math.floor(100*b[a.target.id].current/a.target.duration),c;for(c in b[a.target.id]._progress_markers)d>=c&&c>b[a.target.id].greatest_marker&&(b[a.target.id].greatest_marker=c);b[a.target.id].greatest_marker&&!b[a.target.id]._progress_markers[b[a.target.id].greatest_marker]&&(b[a.target.id]._progress_markers[b[a.target.id].greatest_marker]=!0,dataLayer.push({event:"gaEvent",category:"HTML5 Video",
action:"Progress: "+b[a.target.id].greatest_marker+"% ("+b[a.target.id].current+" seconds)",label:decodeURIComponent(a.target.currentSrc.split("/")[a.target.currentSrc.split("/").length-1])}));break;case "play":dataLayer.push({event:"gaEvent",category:"HTML5 Video",action:"Play",label:decodeURIComponent(a.target.currentSrc.split("/")[a.target.currentSrc.split("/").length-1])});break;case "pause":dataLayer.push({event:"gaEvent",category:"HTML5 Video",action:"Pause ("+b[a.target.id].greatest_marker+
"% - "+b[a.target.id].current+" seconds)",label:decodeURIComponent(a.target.currentSrc.split("/")[a.target.currentSrc.split("/").length-1])});break;case "ended":dataLayer.push({event:"gaEvent",category:"HTML5 Video",action:"Finished",label:decodeURIComponent(a.target.currentSrc.split("/")[a.target.currentSrc.split("/").length-1])})}}for(var g=10,b={},e=document.getElementsByTagName("video"),d=0;d<e.length;d++){if(e[d].getAttribute("id"))var c=e[d].getAttribute("id");else c="html5_video_"+Math.random().toString(36).slice(2),
e[d].setAttribute("id",c);b[c]={};b[c].greatest_marker=0;b[c]._progress_markers={};for(j=0;100>j;j++)b[c].progress_point=g*Math.floor(j/g),b[c]._progress_markers[b[c].progress_point]=!1;b[c].current=0;e[d].addEventListener("play",f,!1);e[d].addEventListener("pause",f,!1);e[d].addEventListener("ended",f,!1);e[d].addEventListener("timeupdate",f,!1)}})();</script><div id="onetrust-consent-sdk"><div class="onetrust-pc-dark-filter ot-hide ot-fade-in" style="display: none;
                    transition: visibility 0s 500ms, opacity 500ms linear;
                    opacity: 0;visibility: hidden;"></div><div id="onetrust-banner-sdk" class="otFloatingRoundedIcon default ot-wo-title" tabindex="0" style="display: none;
                    transition: visibility 0s 400ms, opacity 400ms linear;
                    opacity: 0;visibility: hidden;"><div role="alertdialog" aria-describedby="onetrust-policy-text" aria-label="Privacy"><!-- Cookie Button --><div id="onetrust-cookie-btn-container"><button class="ot-link-btn" id="onetrust-cookie-btn" role="button" aria-label="Cookies"><svg width="65" height="65" viewBox="-2 -2 35 35" xmlns="http://www.w3.org/2000/svg"><title>Cookies Button</title><g fill="none" fill-rule="evenodd"><circle cx="15" cy="15" r="16.5" fill="#2e3643"></circle><circle cx="15" cy="15" r="14.5" fill="#fff"></circle><circle cx="15" cy="15" r="14" fill="#2e3643"></circle><path d="M25 14.95V15c0 5.523-4.477 10-10 10S5 20.523 5 15c0-4.842 3.442-8.881 8.013-9.803A3.5 3.5 0 0 0 16.13 8.98a4 4 0 0 0 6.025 4.39A2.501 2.501 0 0 0 25 14.95z" stroke="#323F4E" stroke-width=".5" fill="#FFF"></path><circle fill="#BDBDBD" cx="10" cy="12" r="2"></circle><circle fill="#BDBDBD" cx="12.5" cy="19.5" r="1.5"></circle><circle fill="#BDBDBD" cx="20" cy="18" r="2"></circle><circle fill="#6CC04A" cx="14" cy="14" r="1"></circle><circle fill="#6CC04A" cx="17" cy="22" r="1"></circle><circle fill="#6CC04A" cx="9" cy="18" r="1"></circle></g></svg></button></div><div class="banner-content"><div class="ot-sdk-container"><!-- Cookie Button END --><div class="ot-sdk-row"><div id="onetrust-group-container" class="ot-sdk-eight ot-sdk-columns"><div class="banner_logo"></div><div id="onetrust-policy"><p id="onetrust-policy-text">By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. For more information on our cookies policy or how BeiGene processes your personal information, please see our<a href="https://www.beigene.com/privacy-policy" aria-label="More information about your privacy">Privacy Policy.</a></p></div></div><div id="onetrust-button-group-parent" class="ot-sdk-three ot-sdk-columns"><div id="onetrust-button-group" class="ot-sdk-row"><div id="onetrust-accept-btn-container"><button id="onetrust-accept-btn-handler">Accept All Cookies</button></div><div id="onetrust-pc-btn-container"><button id="onetrust-pc-btn-handler">Select Cookies</button></div></div></div></div></div><!-- Close Button --><div id="onetrust-close-btn-container"><button class="onetrust-close-btn-handler onetrust-close-btn-ui banner-close-button ot-close-icon" aria-label="Close"></button></div><!-- Close Button END --></div></div></div><div id="onetrust-pc-sdk" class="otPcPanel ot-hide ot-fade-in right ot-slide-out-right" role="alertdialog" aria-modal="true" aria-describedby="ot-pc-desc" lang="en" aria-label="Privacy Preference Center" style="display: none;
                    transition: visibility 0s 500ms, opacity 500ms linear;
                    opacity: 0;visibility: hidden;"><!-- PC Header --><div class="ot-pc-header"><div class="ot-pc-logo" role="img" aria-label="Company Logo" style="background-image: url(&quot;https://cdn.cookielaw.org/logos/51fa3978-59cb-4e5a-8700-81a96d2641f1/0833d948-a2a2-41e9-9fb1-4c4ddacbf904/aac7261a-d664-480d-a811-d8b8b0818876/BGNE-LOGO-HORZ-2C-PMS485-2380.png&quot;);
                    background-position: left;"></div><button id="close-pc-btn-handler" class="ot-close-icon" aria-label="Close"></button></div><div id="ot-pc-content" class="ot-pc-scrollbar"><h2 id="ot-pc-title">Privacy Preference Center</h2><div id="ot-pc-desc">When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
                <br><a href="https://cookiepedia.co.uk/giving-consent-to-cookies" class="privacy-notice-link" rel="noopener" target="_blank" aria-label="More information about your privacy, opens in a new tab">More information</a></div><button id="accept-recommended-btn-handler">Allow All</button><section class="ot-sdk-row ot-cat-grp"><h3 id="ot-category-title"> Manage Consent Preferences</h3><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="C0001"><button ot-accordion="true" aria-expanded="false" aria-controls="ot-desc-id-C0001" aria-labelledby="ot-header-id-C0001"></button><!-- Accordion header --><div class="ot-acc-hdr ot-always-active-group"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-C0001">Strictly Necessary Cookies</h4><div class="ot-always-active">Always Active</div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-C0001">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. &nbsp; &nbsp;You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.</p></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="C0003"><button ot-accordion="true" aria-expanded="false" aria-controls="ot-desc-id-C0003" aria-labelledby="ot-header-id-C0003"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-C0003">Functional Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0003" id="ot-group-id-C0003" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0003" aria-labelledby="ot-header-id-C0003" checked=""> <label class="ot-switch" for="ot-group-id-C0003"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Functional Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-C0003">These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. &nbsp; &nbsp;If you do not allow these cookies then some or all of these services may not function properly.</p></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="C0004"><button ot-accordion="true" aria-expanded="false" aria-controls="ot-desc-id-C0004" aria-labelledby="ot-header-id-C0004"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-C0004">Targeting Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0004" id="ot-group-id-C0004" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0004" aria-labelledby="ot-header-id-C0004" checked=""> <label class="ot-switch" for="ot-group-id-C0004"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Targeting Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-C0004">These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. &nbsp; &nbsp;They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.</p></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="C0002"><button ot-accordion="true" aria-expanded="false" aria-controls="ot-desc-id-C0002" aria-labelledby="ot-header-id-C0002"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-C0002">Performance Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0002" id="ot-group-id-C0002" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0002" aria-labelledby="ot-header-id-C0002" checked=""> <label class="ot-switch" for="ot-group-id-C0002"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Performance Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-C0002">These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. &nbsp; &nbsp;All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.</p></div></div><!-- Non Accordion Group --><!-- Accordion Group section starts --><!-- Accordion Group section ends --></section></div><section id="ot-pc-lst" class="ot-hide ot-pc-scrollbar"><div id="ot-pc-hdr"><div id="ot-lst-title"><button class="ot-link-btn back-btn-handler" aria-label="Back"><svg id="ot-back-arw" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 444.531 444.531" xml:space="preserve"><title>Back Button</title><g><path fill="#656565" d="M213.13,222.409L351.88,83.653c7.05-7.043,10.567-15.657,10.567-25.841c0-10.183-3.518-18.793-10.567-25.835
          l-21.409-21.416C323.432,3.521,314.817,0,304.637,0s-18.791,3.521-25.841,10.561L92.649,196.425
          c-7.044,7.043-10.566,15.656-10.566,25.841s3.521,18.791,10.566,25.837l186.146,185.864c7.05,7.043,15.66,10.564,25.841,10.564
          s18.795-3.521,25.834-10.564l21.409-21.412c7.05-7.039,10.567-15.604,10.567-25.697c0-10.085-3.518-18.746-10.567-25.978
          L213.13,222.409z"></path></g></svg></button><h3>Back</h3></div><div class="ot-lst-subhdr"><div class="ot-search-cntr"><p role="status" class="ot-scrn-rdr"></p><label for="vendor-search-handler" class="ot-scrn-rdr"></label> <input id="vendor-search-handler" type="text" name="vendor-search-handler"> <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 -30 110 110" aria-hidden="true"><title>Search Icon</title><path fill="#2e3644" d="M55.146,51.887L41.588,37.786c3.486-4.144,5.396-9.358,5.396-14.786c0-12.682-10.318-23-23-23s-23,10.318-23,23
            s10.318,23,23,23c4.761,0,9.298-1.436,13.177-4.162l13.661,14.208c0.571,0.593,1.339,0.92,2.162,0.92
            c0.779,0,1.518-0.297,2.079-0.837C56.255,54.982,56.293,53.08,55.146,51.887z M23.984,6c9.374,0,17,7.626,17,17s-7.626,17-17,17
            s-17-7.626-17-17S14.61,6,23.984,6z"></path></svg></div><div class="ot-fltr-cntr"><button id="filter-btn-handler" aria-label="Filter" aria-haspopup="true"><svg role="presentation" aria-hidden="true" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 402.577 402.577" xml:space="preserve"><title>Filter Icon</title><g><path fill="#fff" d="M400.858,11.427c-3.241-7.421-8.85-11.132-16.854-11.136H18.564c-7.993,0-13.61,3.715-16.846,11.136
      c-3.234,7.801-1.903,14.467,3.999,19.985l140.757,140.753v138.755c0,4.955,1.809,9.232,5.424,12.854l73.085,73.083
      c3.429,3.614,7.71,5.428,12.851,5.428c2.282,0,4.66-0.479,7.135-1.43c7.426-3.238,11.14-8.851,11.14-16.845V172.166L396.861,31.413
      C402.765,25.895,404.093,19.231,400.858,11.427z"></path></g></svg></button></div><div id="ot-anchor"></div><section id="ot-fltr-modal"><div id="ot-fltr-cnt"><button id="clear-filters-handler">Clear</button><div class="ot-fltr-scrlcnt ot-pc-scrollbar"><div class="ot-fltr-opts"><div class="ot-fltr-opt"><div class="ot-chkbox"><input id="chkbox-id" type="checkbox" aria-checked="false" class="category-filter-handler"> <label for="chkbox-id"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div><div class="ot-fltr-btns"><button id="filter-apply-handler">Apply</button> <button id="filter-cancel-handler">Cancel</button></div></div></div></section></div></div><section id="ot-lst-cnt" class="ot-pc-scrollbar"><div id="ot-sel-blk"><div class="ot-sel-all"><div class="ot-sel-all-hdr"><span class="ot-consent-hdr">Consent</span> <span class="ot-li-hdr">Leg.Interest</span></div><div class="ot-sel-all-chkbox"><div class="ot-chkbox" id="ot-selall-hostcntr"><input id="select-all-hosts-groups-handler" type="checkbox" aria-checked="false"> <label for="select-all-hosts-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-vencntr"><input id="select-all-vendor-groups-handler" type="checkbox" aria-checked="false"> <label for="select-all-vendor-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-licntr"><input id="select-all-vendor-leg-handler" type="checkbox" aria-checked="false"> <label for="select-all-vendor-leg-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div></div><div class="ot-sdk-row"><div class="ot-sdk-column"></div></div></section></section><!-- Footer buttons and logo --><div class="ot-pc-footer"><div class="ot-btn-container"> <button class="save-preference-btn-handler onetrust-close-btn-handler">Confirm My Choices</button></div><div class="ot-pc-footer-logo"><a href="https://www.onetrust.com/products/cookie-consent/" target="_blank" rel="noopener noreferrer" aria-label="Powered by OneTrust Opens in a new Tab"><img alt="Powered by Onetrust" src="https://cdn.cookielaw.org/logos/static/poweredBy_ot_logo.svg" title="Powered by OneTrust Opens in a new Tab"></a></div></div><!-- Cookie subgroup container --><!-- Vendor list link --><!-- Cookie lost link --><!-- Toggle HTML element --><!-- Checkbox HTML --><!-- Arrow SVG element --><!-- plus minus--><!-- Accordion basic element --><span class="ot-scrn-rdr" aria-atomic="true" aria-live="polite">Your Privacy [`dialog closed`]</span><!-- Vendor Service container and item template --><iframe class="ot-text-resize" title="onetrust-text-resize" style="position: absolute; top: -50000px; width: 100em;" aria-hidden="true"></iframe></div></div></body></html>